{"gene":"ABCA1","run_date":"2026-06-09T22:02:36","timeline":{"discoveries":[{"year":2000,"finding":"ABCA1 mediates active transport of cellular cholesterol and phospholipids to lipid-poor apolipoproteins (especially apoA-I), establishing the first step of reverse cholesterol transport and HDL particle formation. Loss-of-function mutations in ABCA1 cause Tangier disease.","method":"Genetic linkage/mutation analysis in Tangier disease patients combined with cellular cholesterol efflux assays","journal":"Current opinion in lipidology","confidence":"High","confidence_rationale":"Tier 2 / Strong — replicated across multiple labs, human genetic disease causation confirmed, cellular efflux assays consistent across studies","pmids":["10882340","11111099","11483617"],"is_preprint":false},{"year":2006,"finding":"Purified human ABCA1 reconstituted in liposomes displays robust ATPase activity that is stimulated preferentially by phosphatidylcholine and sphingomyelin, inhibited by cholesterol in a structure-specific manner (beta-sitosterol and campesterol inhibit; stigmasterol does not), and suppressed by glibenclamide, providing the first direct biochemical evidence of ABCA1 enzymatic mechanism.","method":"Purification of human ABCA1 from insect Sf9 cells, reconstitution in liposomes, in vitro ATPase assay with pharmacological and lipid modulators","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with purified protein, multiple substrate/inhibitor conditions tested in single rigorous study","pmids":["16500904"],"is_preprint":false},{"year":2007,"finding":"ABCA1 activity creates two types of high-affinity apoA-I binding sites at the cell surface: a low-capacity site formed by direct apoA-I/ABCA1 interaction (regulatory role, ~10% of surface-bound apoA-I) and a much higher-capacity site formed by apoA-I interacting with ABCA1-generated lipid domains (functions in nascent HDL assembly). The C-terminal domain of apoA-I is required for lipid-domain binding but not for direct ABCA1 binding.","method":"Radiolabeled apoA-I binding assays on J774 macrophages, covalent cross-linking to ABCA1, SDS-PAGE analysis, C-terminal deletion mutants of apoA-I","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — cross-linking, saturable binding analysis, mutagenesis of apoA-I, multiple orthogonal methods in single study","pmids":["17478755"],"is_preprint":false},{"year":2008,"finding":"ABCA1 and apoA-I undergo retroendocytosis via a clathrin- and Rab5-mediated pathway; approximately 30% of endocytosed ABCA1 is recycled back to the cell surface via a Rab4-mediated route. Blocking receptor-mediated endocytosis increases cell-surface ABCA1 but decreases apoA-I-mediated cholesterol efflux from cells with accumulated lipoprotein-derived cholesterol, indicating the retroendocytosis pathway contributes to HDL formation.","method":"Extracellular HA-tagged and intracellular GFP-tagged ABCA1 constructs, endocytosis/recycling assays, dominant-negative Rab GTPase constructs, cholesterol efflux assays","journal":"Genes to cells : devoted to molecular & cellular mechanisms","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal live-cell imaging and functional approaches, single lab","pmids":["19170766"],"is_preprint":false},{"year":2005,"finding":"Unsaturated fatty acids destabilize ABCA1 protein and impair lipid transport through a phospholipase D2 (PLD2)-dependent pathway: activated unsaturated acyl-CoA derivatives stimulate PLD2, which generates diacylglycerols that promote serine phosphorylation of ABCA1, leading to enhanced ABCA1 degradation.","method":"PLD inhibitor (1-butanol), PLD2 activator (mastoparan), PLD2 siRNA knockdown, acyl-CoA synthetase inhibitor (triacsin C), ABCA1 serine phosphorylation measurement, cholesterol efflux assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological and genetic (siRNA) approaches, single lab with multiple orthogonal methods","pmids":["16118212"],"is_preprint":false},{"year":2003,"finding":"Retinoic acid receptors RARγ and RARα (but not RARβ) directly bind the DR4 element in the ABCA1 promoter and induce ABCA1 mRNA and protein expression in macrophages, operating through the same promoter element as LXR/RXR. In RARγ-/- macrophages, high RARα compensates for absent RARγ.","method":"Cellular cotransfection with RAR/RXR and ABCA1 promoter-reporter constructs, chromatin immunoprecipitation (ChIP), RARγ knockout mice, dose-response with ATRA and TTNPB","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — ChIP confirming in vivo promoter binding, cotransfection reporter assays, knockout validation, multiple methods single lab","pmids":["14560020"],"is_preprint":false},{"year":2004,"finding":"ABCA1 directly associates with syntaxin 13 (but not syntaxins 3 or 6) and flotillin-1 in lipid raft microdomains and phagosomes. Syntaxin 13 siRNA knockdown reduces ABCA1 protein levels and decreases apoA-I-dependent choline-phospholipid efflux. ABCA1 is identified as a phagosomal protein involved in vesicular lipid transport.","method":"Co-immunoprecipitation, immunofluorescence microscopy, siRNA knockdown of syntaxin 13, detergent-resistant microdomain fractionation, cholesterol/phospholipid efflux assay","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, immunofluorescence colocalization, siRNA functional validation, multiple methods single lab","pmids":["15469992"],"is_preprint":false},{"year":2007,"finding":"Beta-cell-specific inactivation of Abca1 in mice causes markedly impaired glucose tolerance and defective insulin secretion (with normal insulin sensitivity), associated with altered islet cholesterol homeostasis. Rosiglitazone requires beta-cell Abca1 for its beneficial effects on glucose tolerance, establishing ABCA1 as a regulator of beta-cell cholesterol homeostasis and insulin secretion.","method":"Conditional beta-cell-specific ABCA1 knockout mice, glucose tolerance tests, insulin secretion assays in isolated islets in vitro, rosiglitazone treatment","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type-specific KO with defined metabolic phenotype, validated in vivo and in vitro, replicated by miR-33a study","pmids":["17322896"],"is_preprint":false},{"year":2008,"finding":"OSBP (oxysterol-binding protein) negatively regulates ABCA1 protein stability by a sterol-binding domain-dependent mechanism: OSBP silencing increases ABCA1 protein half-life by 3-fold without affecting ABCA1 mRNA or LXR transcriptional activity. A sterol-binding domain mutation in OSBP abolishes its destabilizing effect on ABCA1.","method":"RNAi knockdown of OSBP in CHO cells and J774 macrophages, ABCA1 half-life measurement (cycloheximide chase), ABCA1 mRNA quantification, OSBP domain mutant transfection, cholesterol efflux assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — protein stability assay, genetic (RNAi) and domain mutant approaches, multiple cell types, single lab","pmids":["18450749"],"is_preprint":false},{"year":2007,"finding":"ORP8 localizes to the endoplasmic reticulum, binds 25-hydroxycholesterol, and acts as a negative regulator of ABCA1 transcription in macrophages: ORP8 silencing by RNAi increases ABCA1 expression and cholesterol efflux to apoA-I, an effect partially mediated through the DR4 and E-box elements in the ABCA1 promoter and synergizing with LXR activation.","method":"ORP8 siRNA knockdown in THP-1 macrophages, ABCA1 promoter-luciferase reporter assay with DR4 and E-box mutations, subcellular localization by ER markers, cholesterol efflux assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA functional validation, reporter mutagenesis, single lab with multiple methods","pmids":["17991739"],"is_preprint":false},{"year":2009,"finding":"LRP1 deficiency increases PDGFRβ/MAPK signaling, leading to phosphorylation and activation of cytosolic phospholipase A2 (cPLA2), which releases arachidonic acid that suppresses LXR/RXR activation at the ABCA1 promoter, resulting in greatly reduced ABCA1 expression and impaired cholesterol efflux.","method":"LRP1-deficient cells, MAPK pathway inhibitors, cPLA2 phosphorylation assays, LXR/RXR reporter assays, ABCA1 expression and cholesterol efflux measurements","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and pharmacological dissection of pathway, single lab, multiple methods","pmids":["19718435"],"is_preprint":false},{"year":2012,"finding":"miR-33a directly suppresses ABCA1 expression in pancreatic islets via binding to the 3'UTR of ABCA1 mRNA, reducing glucose-stimulated insulin secretion and increasing islet cholesterol. miR-33a-induced insulin secretion defects are rescued by cholesterol depletion or ABCA1 overexpression, confirming the causal link between ABCA1-mediated cholesterol efflux and beta-cell function.","method":"Adenoviral miR-33a overexpression in human and mouse islets, anti-miRNA treatment, cholesterol depletion (methyl-β-cyclodextrin, mevastatin), ABCA1 overexpression in beta-cell-specific ABCA1 KO islets, glucose-stimulated insulin secretion assays","journal":"Diabetes","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple gain/loss-of-function approaches, rescue experiments, consistent with independent ABCA1 beta-cell KO study","pmids":["22315319"],"is_preprint":false},{"year":2014,"finding":"RNA-binding protein HuR directly binds the 3'UTR of ABCA1 mRNA (demonstrated by RNA immunoprecipitation) and increases ABCA1 translation. HuR silencing reduces ABCA1 protein expression and cholesterol efflux to apoA-I. Cellular cholesterol levels regulate HuR expression, localization, and its interaction with ABCA1 mRNA.","method":"RNA immunoprecipitation (RIP) assay, HuR siRNA knockdown in Huh-7 and THP-1 cells, ABCA1 protein and mRNA quantification, cholesterol efflux assays","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct RIP demonstrating mRNA binding, siRNA functional validation, single lab two cell types","pmids":["24729624"],"is_preprint":false},{"year":2015,"finding":"Apoptotic cells trigger ABCA1 upregulation via a plasma membrane-initiated signaling pathway involving the phagocytic receptor BAI1 (recognizing phosphatidylserine), and intracellular intermediates ELMO1 and Rac1. This pathway operates independently of LXR sterol-sensing machinery; macrophages from BAI1-/- mice show attenuated ABCA1 induction.","method":"BAI1-/-, ELMO1-/-, and Rac1-deficient primary macrophages, BAI1 transgenic mice overexpressing BAI1, ABCA1 mRNA and protein induction assays, high-fat diet in vivo model","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Moderate — multiple genetic KO models and transgenic rescue, in vivo validation, defined pathway components, single focused study","pmids":["26075824"],"is_preprint":false},{"year":2019,"finding":"ApoE4 promotes greater ARF6 expression than ApoE3, trapping ABCA1 in late endosomes and impairing its recycling to the plasma membrane. This results in lower ABCA1-mediated cholesterol efflux, greater lipid-free ApoE4 particles, and lower Aβ degradation capacity. Enhancing ABCA1 activity reduces ApoE4 aggregation and ABCA1 aggregation in hippocampus.","method":"ARF6 expression measurement in APOE3 vs APOE4 astrocytes, ABCA1 subcellular localization by fluorescence microscopy, cholesterol efflux activity assays, human CSF from APOE3/3 vs APOE4/4 carriers, ApoE4 targeted replacement mice","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cellular localization with functional consequence, in vivo mouse model, human CSF validation, single lab","pmids":["31641056"],"is_preprint":false},{"year":2022,"finding":"ABCA1 functions as an extracellular phospholipid translocase that extracts phospholipids from the outer leaflet of the plasma membrane (not as a floppase translocating from inner to outer leaflet). Simulations identified a gateway domain and annulus orifice forming a hydrophobic tunnel in the extracellular domain; engineered mutations in these domains strongly inhibit lipid export without affecting cell-surface ABCA1 expression.","method":"Molecular dynamics simulations, site-directed mutagenesis of gateway and annulus residues, ABCA1 cell-surface expression assays, lipid export functional assays","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 1-2 / Moderate — computational model supported by mutagenesis and functional assay, single study","pmids":["35974019"],"is_preprint":false},{"year":2016,"finding":"TRAK2 is a negative regulator of LXR-mediated ABCA1 expression: TRAK2 siRNA knockdown increases ABCA1 mRNA and protein, enhances cholesterol efflux to apoA-I and HDL, and increases LXR binding at the ABCA1 promoter (by ChIP). The effect of TRAK2 knockdown on cholesterol efflux is abolished in ABCA1-deficient cells, confirming ABCA1 dependence.","method":"TRAK2 siRNA in THP-1 and HepG2 cells, chromatin immunoprecipitation of LXR at ABCA1 promoter, ABCA1 mRNA/protein quantification, cholesterol efflux assays, ABCA1 KO cells","journal":"European heart journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, siRNA, ABCA1 KO rescue, multiple methods single lab","pmids":["28655204"],"is_preprint":false},{"year":2017,"finding":"Plasminogen (PLG) promotes cholesterol efflux specifically through the ABCA1 pathway, and this PLG-dependent efflux is inhibited by lipoprotein(a) [Lp(a)], identifying PLG as a non-HDL acceptor for ABCA1-mediated cholesterol efflux.","method":"Genetic mouse models (APOA1-, APOE-, APOA4-deficient), size-exclusion chromatography of plasma fractions, ion-exchange chromatography, shotgun proteomics, human PLG cholesterol efflux assays with ABCA1-expressing cells","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic models plus biochemical fractionation and proteomics, functional efflux assay, single study","pmids":["28768900"],"is_preprint":false},{"year":2019,"finding":"PMP22 physically interacts with ABCA1 at the Schwann cell plasma membrane (co-immunoprecipitation from nerve lysates); loss of PMP22 reduces ABCA1 membrane localization, decreases apoE secretion, and impairs ABCA1-mediated cholesterol efflux, while ABCA1 KO upregulates PMP22 expression.","method":"Co-immunoprecipitation from Schwann cell and nerve lysates, PMP22 KO and ABCA1 KO mice, immunofluorescence localization, cholesterol efflux assays, electrophysiology (membrane capacitance/resistance)","journal":"The Journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP, KO mouse functional phenotype, multiple methods single lab","pmids":["31061090"],"is_preprint":false},{"year":2015,"finding":"High glucose inhibits LXR-dependent ABCA1 expression in macrophages through reduction of PRMT2 (protein arginine methyltransferase 2); PRMT2-/- macrophages have reduced ABCA1 expression and ABCA1-mediated cholesterol efflux, while monocytes from diabetic mice show decreased PRMT2.","method":"RAW 264.7 and BMDM cells in normal vs. high glucose, chromatin-modifying enzyme expression survey, PRMT2-/- mice, LXR reporter assays, ABCA1 expression and cholesterol efflux assays, diabetic mouse monocytes","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse validation, in vitro and in vivo correlation, single lab","pmids":["26288135"],"is_preprint":false},{"year":2017,"finding":"AGE-albumin (advanced glycation end-products) accelerates ABCA1 degradation through both ubiquitin-proteasome and lysosomal pathways in macrophages, dependent on RAGE signaling (RAGE siRNA prevents ABCA1 reduction). Calpain inhibition does not rescue ABCA1 under AGE-albumin, unlike baseline ABCA1 degradation.","method":"Cycloheximide chase assay, proteasome inhibitor (MG-132), lysosomal inhibitor (ammonium chloride), calpain inhibitors, ABCA1 immunoprecipitation and ubiquitination assay, RAGE siRNA knockdown in THP-1 cells","journal":"Journal of diabetes and its complications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pathway inhibitors and RAGE siRNA, ubiquitination confirmed by IP, single lab","pmids":["29097054"],"is_preprint":false},{"year":2016,"finding":"AMPK activation increases ABCA1 and LXRα mRNA and protein in human macrophages through LXRα binding to the LXR responsive element in the ABCA1 promoter (confirmed by ChIP). LXRα silencing attenuates ABCA1 expression after AMPK activation; AMPK knockdown decreases ABCA1 and LXRα expression.","method":"Pharmacological and genetic AMPK activation/knockdown in THP-1 and primary human macrophages, LXRα/β siRNA, chromatin immunoprecipitation, luciferase reporter assay, cholesterol efflux assays","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, siRNA knockdown, reporter assays, single lab multiple methods","pmids":["27343431"],"is_preprint":false},{"year":2015,"finding":"CXCL12, acting through CXCR4, activates the GSK3β/β-catenin(T120)/TCF21 signaling pathway to suppress ABCA1 transcription in macrophages: CXCL12 phosphorylates GSK3β and β-catenin(T120), inhibiting TCF21, which normally drives ABCA1 promoter activity. CXCR4 knockdown or inhibition blocks these effects.","method":"Luciferase reporter and ChIP assays for TCF21 binding at ABCA1 promoter, GSK3β/β-catenin phosphorylation by western blot, CXCR4 inhibition/knockdown, lentiviral CXCL12 overexpression in ApoE-/- mice, cholesterol efflux assays","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP, reporter assays, genetic in vivo validation, multiple methods single lab","pmids":["31662443"],"is_preprint":false},{"year":2019,"finding":"ABCA1 modulates intraocular pressure by regulating aqueous humor outflow through a caveolin-1/endothelial NOS/NO signaling pathway: ABCA1 upregulation decreases caveolin-1 and increases eNOS expression and NO production in angular aqueous plexus cells, decreasing transendothelial resistance; ABCA1 downregulation has opposite effects. Intracameral injection of LXR agonist GW3965 decreases IOP in vivo.","method":"ABCA1 shRNA lentiviral knockdown, LXR agonist GW3965 treatment, transendothelial electrical resistance measurement, eNOS/caveolin-1/NO quantification, intracameral injection in animal model, IOP and outflow facility measurement","journal":"Investigative ophthalmology & visual science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain and loss of function with molecular pathway delineation, in vitro and in vivo, single lab","pmids":["32428234"],"is_preprint":false},{"year":2020,"finding":"ABCA1 mutations in CMML patients confer a proliferative advantage to myeloid cells; mechanistically, ABCA1 mutations increase IL-3Rβ signaling via MAPK and JAK2, causing metabolic reprogramming. In vivo inactivation or expression of ABCA1 mutants in hematopoietic cells (in Tet2-/- background) promotes myeloproliferation. ApoA-I transgene overexpression dampens myeloproliferation, bypassing ABCA1 defects.","method":"Somatic mutation sequencing in CMML patients, in vivo hematopoietic ABCA1 inactivation and mutant expression in mice, IL-3Rβ/MAPK/JAK2 signaling assays, apoA-I transgene rescue","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KO and mutant expression with defined signaling pathway, human mutation data, single study","pmids":["32160545"],"is_preprint":false},{"year":2025,"finding":"Caveolin-1, a sensor of cellular cholesterol accumulation, promotes ABCA1 endolysosomal trafficking and lysosomal trapping. In APOE4 and AD models, oxysterol accumulation increases caveolin-1 and ABCA1 expression, trapping ABCA1 in lysosomes, activating mTORC1, and driving cellular senescence. Cyclodextrin treatment reduces brain oxysterol levels, ABCA1 lysosomal trapping, mTORC1 activation, and senescence markers in APOE4-TR mice.","method":"Unbiased discovery proteomics to identify caveolin-1 as ABCA1 trafficking mediator, ABCA1 KO cell lines and mouse models, APOE4-TR mice, iPSC-derived astrocytes, immunofluorescence/immunoblotting, scRNA-seq, cyclodextrin intervention","journal":"Molecular neurodegeneration","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — discovery proteomics plus KO validation plus in vivo rescue, single lab comprehensive study","pmids":["39901180"],"is_preprint":false},{"year":2013,"finding":"Astrocyte-specific ABCA1 controls brain apoE levels in vivo; ABCA1-deficient astrocytes show reduced apoE, whereas neuronal ABCA1 deficiency does not affect apoE levels. Brain ABCA1 deficiency causes cortical astrogliosis, increased MAPK activation, and augmented TLR4-induced inflammatory responses. Microglia lacking ABCA1 show increased TNFα secretion and decreased phagocytosis.","method":"Brain-specific, neuron-specific, and astrocyte-specific ABCA1 conditional KO mice, LPS challenge, MAPK and inflammatory cytokine assays, microglial culture phagocytosis assays, apoE protein quantification","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific KO with defined inflammatory phenotype, multiple conditional KO lines, single lab","pmids":["23376685"],"is_preprint":false},{"year":2009,"finding":"ABCA1 activity suppresses macrophage inflammation by modulating Toll-like receptor (TLR4) signaling; ABCA1 deficiency increases TLR4-mediated inflammatory cytokine and chemokine signaling, mechanistically linking cholesterol efflux to anti-inflammatory function through membrane lipid organization.","method":"ABCA1-deficient macrophages (from KO mice), TLR4 stimulation assays, inflammatory cytokine/chemokine measurement, sterol efflux assays","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO, defined inflammatory readout, replicated in human mutation carriers study","pmids":["19797709"],"is_preprint":false},{"year":2012,"finding":"ApoA-I/ABCA1 interaction activates multiple downstream signaling pathways including JAK2/STAT3, PKA, Rho family GTPase CDC42, and PKC. PKA and CDC42 activation regulate ABCA1-mediated lipid efflux; PKC activation stabilizes ABCA1 protein; JAK2/STAT3 activation regulates both lipid efflux and anti-inflammatory function.","method":"Pharmacological and genetic modulation of signaling kinases in ABCA1-expressing cells, lipid efflux assays, ABCA1 protein stability assays, anti-inflammatory readouts (reviewed and validated by multiple groups)","journal":"Molecular medicine (Cambridge, Mass.)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple signaling pathways validated by pharmacological and genetic approaches across studies, review integrating original data","pmids":["22064972"],"is_preprint":false},{"year":2015,"finding":"TLR4 signaling via IRAK1 downregulates ABCA1 expression and promotes lipid accumulation in vascular smooth muscle cells (VSMCs). IRAK1 siRNA knockdown reverses oxLDL/TLR4-induced ABCA1 downregulation. In TLR4 KO mice on a high-fat diet, IRAK1 expression and lipid accumulation are reduced with concomitant restoration of ABCA1.","method":"IRAK1 siRNA in primary cultured VSMCs, TLR4 KO mice on HFD, oxLDL stimulation, ABCA1 expression and lipid accumulation assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA functional validation and in vivo TLR4 KO, single lab","pmids":["26512959"],"is_preprint":false},{"year":2011,"finding":"Hepatic ABCA1 is required for nascent HDL particle assembly; hepatocyte-specific ABCA1 KO (HSKO) mice show increased hepatic secretion of large TG-enriched VLDL1 particles, 50% lower LDL, and 80% reduction in HDL, with hypercatabolism of apoA-I by the kidney. Silencing ABCA1 in hepatoma cells reduces PI3K activation and increases secretion of large TG-enriched VLDL1, linking hepatic ABCA1 to VLDL metabolism.","method":"Hepatocyte-specific ABCA1 KO mice, ABCA1 siRNA in McArdle rat hepatoma cells, plasma lipoprotein profiling, VLDL secretion assays, PI3K activity measurement","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — tissue-specific KO with defined lipoprotein phenotype, cell-based siRNA validation, single lab","pmids":["22001232"],"is_preprint":false},{"year":2016,"finding":"Piperine stabilizes ABCA1 protein by inhibiting calpain-mediated ABCA1 degradation, increasing ABCA1 half-life without affecting ABCA1 mRNA levels, thereby promoting cholesterol efflux from macrophages.","method":"Cycloheximide chase assay, calpain activity inhibition assay, ABCA1 mRNA and protein quantification in THP-1 macrophages, cholesterol efflux assays","journal":"Molecular nutrition & food research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pharmacological approach only, single lab, no direct calpain-ABCA1 reconstitution","pmids":["27862930"],"is_preprint":false}],"current_model":"ABCA1 is an ATP-hydrolyzing integral membrane transporter that extracts phospholipids from the outer leaflet of the plasma membrane and flips them through a hydrophobic gateway/annulus tunnel into extracellular apoA-I, simultaneously generating lipid domains on the cell surface to which apoA-I binds (directly to ABCA1 at ~10% capacity and to lipid microdomains at ~90% capacity), enabling solubilization of cholesterol and phospholipids into nascent discoidal HDL particles; its activity is regulated transcriptionally by LXR/RXR, RAR, PPAR, AMPK-LXRα, HIF-1β, and multiple repressors (OSBP, ORP8, TRAK2, p62/mTOR), post-translationally by calpain-mediated degradation (destabilized by unsaturated fatty acid–activated PLD2 phosphorylation, AGE-RAGE-ubiquitin/lysosome pathways, and OSBP), and by endosomal recycling (clathrin/Rab5 endocytosis; Rab4/ARF6-regulated return to plasma membrane); beyond cholesterol efflux, ABCA1 suppresses TLR4-driven macrophage inflammation through membrane lipid raft remodeling, activates JAK2/STAT3, PKA, PKC, and CDC42 signaling upon apoA-I binding, controls beta-cell cholesterol homeostasis and insulin secretion, regulates hepatic VLDL secretion, modulates aqueous humor outflow via a caveolin-1/eNOS/NO pathway, maintains brain apoE lipidation and neuroinflammatory tone in an astrocyte-specific manner, and exerts tumor-suppressor function in myeloid cells by restraining IL-3Rβ/MAPK/JAK2 signaling."},"narrative":{"mechanistic_narrative":"ABCA1 is an ATP-hydrolyzing integral membrane transporter that drives the rate-limiting first step of reverse cholesterol transport, exporting cellular cholesterol and phospholipids to lipid-poor apolipoproteins—principally apoA-I—to nucleate nascent HDL particles; loss-of-function mutations cause Tangier disease [PMID:10882340, PMID:11111099, PMID:11483617]. The purified protein reconstituted in liposomes hydrolyzes ATP in a manner preferentially stimulated by phosphatidylcholine and sphingomyelin and inhibited by specific sterols, establishing its direct enzymatic mechanism [PMID:16500904], and it operates as an extracellular phospholipid translocase that extracts outer-leaflet phospholipids through a hydrophobic gateway/annulus tunnel in its extracellular domain rather than as an inner-to-outer floppase [PMID:35974019]. ABCA1 activity generates two classes of cell-surface apoA-I binding sites—a minor direct ABCA1/apoA-I site and a dominant high-capacity site formed by apoA-I engaging ABCA1-generated lipid domains, the latter requiring the apoA-I C-terminus and driving HDL assembly [PMID:17478755]. ApoA-I binding additionally triggers JAK2/STAT3, PKA, PKC, and CDC42 signaling that feeds back on lipid efflux, protein stability, and inflammation [PMID:22064972]. The transporter cycles between the plasma membrane and endosomes via clathrin/Rab5-mediated retroendocytosis with Rab4-dependent recycling that contributes to efflux [PMID:19170766], and it partitions into lipid rafts and phagosomes in association with syntaxin 13 and flotillin-1 [PMID:15469992]. ABCA1 abundance is tightly controlled transcriptionally—induced by LXR/RXR, RAR, and AMPK–LXRα, and repressed by ORP8, TRAK2, and CXCL12/CXCR4–GSK3β/TCF21 signaling [PMID:14560020, PMID:28655204, PMID:27343431, PMID:31662443]—and post-translationally through calpain-mediated degradation accelerated by PLD2-dependent serine phosphorylation, OSBP, and AGE–RAGE–ubiquitin/lysosomal pathways [PMID:16118212, PMID:18450749, PMID:29097054]. Beyond efflux, ABCA1 restrains TLR4-driven macrophage inflammation through membrane lipid remodeling [PMID:19797709], governs beta-cell cholesterol homeostasis and insulin secretion [PMID:17322896, PMID:22315319], directs hepatic HDL assembly and VLDL secretion [PMID:22001232], maintains astrocyte apoE lipidation and neuroinflammatory tone [PMID:23376685], and acts as a myeloid tumor suppressor by limiting IL-3Rβ/MAPK/JAK2 signaling [PMID:32160545].","teleology":[{"year":2000,"claim":"Established ABCA1 as the molecular cause of defective cellular cholesterol efflux, defining the first step of reverse cholesterol transport and a human disease gene.","evidence":"Genetic linkage and mutation analysis in Tangier disease patients with cellular cholesterol efflux assays","pmids":["10882340","11111099","11483617"],"confidence":"High","gaps":["Did not resolve the enzymatic transport mechanism","Did not define the lipid substrate or directionality of transport"]},{"year":2003,"claim":"Identified retinoic acid receptors as direct transcriptional inducers of ABCA1 acting through the same promoter DR4 element as LXR/RXR, broadening the regulatory inputs controlling efflux capacity.","evidence":"Promoter-reporter cotransfection, ChIP, and RARγ knockout macrophages","pmids":["14560020"],"confidence":"High","gaps":["Did not establish physiological RAR ligand context","Crosstalk with LXR occupancy not fully resolved"]},{"year":2004,"claim":"Placed ABCA1 in lipid raft microdomains and phagosomes via direct association with syntaxin 13 and flotillin-1, linking it to vesicular lipid transport.","evidence":"Reciprocal co-IP, immunofluorescence, detergent-resistant microdomain fractionation, and syntaxin 13 siRNA","pmids":["15469992"],"confidence":"High","gaps":["Mechanism by which syntaxin 13 stabilizes ABCA1 not defined","Phagosomal lipid handling role not quantified"]},{"year":2005,"claim":"Defined a post-translational destabilization route in which unsaturated fatty acids drive PLD2-dependent serine phosphorylation and accelerated ABCA1 degradation, connecting lipid metabolism to transporter turnover.","evidence":"PLD inhibitors/activators, PLD2 siRNA, acyl-CoA synthetase inhibition, and phosphorylation/efflux assays","pmids":["16118212"],"confidence":"High","gaps":["Kinase mediating ABCA1 serine phosphorylation not identified","Link to calpain degradation pathway not directly tested"]},{"year":2006,"claim":"Provided the first direct biochemical proof of ABCA1 enzymatic activity, showing phospholipid-stimulated, sterol-modulated ATPase activity with purified reconstituted protein.","evidence":"Purification from Sf9 cells, liposome reconstitution, in vitro ATPase assays with lipid and pharmacological modulators","pmids":["16500904"],"confidence":"High","gaps":["Did not resolve coupling of ATP hydrolysis to lipid movement","Structural basis of sterol inhibition not defined"]},{"year":2007,"claim":"Resolved how apoA-I engages the cell surface, distinguishing a minor direct ABCA1-binding site from a dominant ABCA1-generated lipid-domain site responsible for HDL assembly.","evidence":"Radiolabeled apoA-I binding, cross-linking, and apoA-I C-terminal deletion mutants on macrophages","pmids":["17478755"],"confidence":"High","gaps":["Molecular nature of the lipid domain not structurally defined","Relative contribution of each site to net efflux not quantified"]},{"year":2007,"claim":"Demonstrated a tissue-specific physiological role for ABCA1 in beta-cell cholesterol homeostasis and glucose-stimulated insulin secretion, extending function beyond vascular efflux.","evidence":"Beta-cell-specific Abca1 knockout mice with glucose tolerance and islet insulin secretion assays","pmids":["17322896"],"confidence":"High","gaps":["Did not define how islet cholesterol controls secretion machinery","ER ORP8-based transcriptional repression of ABCA1 awaits replication"]},{"year":2007,"claim":"Identified ER-localized ORP8 as a sterol-sensing negative transcriptional regulator of ABCA1 acting through promoter DR4/E-box elements.","evidence":"ORP8 siRNA in THP-1 macrophages with promoter-luciferase mutagenesis and efflux assays","pmids":["17991739"],"confidence":"Medium","gaps":["Single lab; transcription factor linking ORP8 to promoter not identified","In vivo relevance not established"]},{"year":2008,"claim":"Established endosomal cycling as a functional determinant of ABCA1, showing clathrin/Rab5 retroendocytosis with Rab4-dependent recycling that supports efflux from lipid-loaded cells.","evidence":"Dual-tagged ABCA1 constructs, dominant-negative Rab GTPases, and efflux assays","pmids":["19170766"],"confidence":"High","gaps":["Sorting signals directing recycling versus degradation not mapped","Fraction of efflux attributable to recycling not generalized across cell types"]},{"year":2008,"claim":"Identified OSBP as a sterol-binding-domain-dependent destabilizer of ABCA1 protein, distinct from transcriptional control.","evidence":"OSBP RNAi, cycloheximide-chase half-life measurement, and OSBP domain mutants in CHO and J774 cells","pmids":["18450749"],"confidence":"High","gaps":["Degradation machinery engaged by OSBP not identified","Direct OSBP-ABCA1 interaction not demonstrated"]},{"year":2009,"claim":"Connected ABCA1-mediated efflux to anti-inflammatory function, showing ABCA1 deficiency amplifies TLR4 signaling through membrane lipid organization.","evidence":"ABCA1-deficient macrophages with TLR4 stimulation and cytokine/efflux readouts","pmids":["19797709"],"confidence":"Medium","gaps":["Precise lipid raft change driving TLR4 sensitization not defined","Causal separation of efflux from membrane remodeling incomplete"]},{"year":2009,"claim":"Defined an upstream signaling axis (LRP1 loss → PDGFRβ/MAPK → cPLA2 → arachidonic acid) that suppresses LXR-driven ABCA1 transcription.","evidence":"LRP1-deficient cells, MAPK inhibitors, cPLA2 phosphorylation, and LXR/RXR reporter and efflux assays","pmids":["19718435"],"confidence":"Medium","gaps":["Single lab; in vivo validation limited","Mechanism of arachidonic acid LXR inhibition not detailed"]},{"year":2011,"claim":"Established hepatic ABCA1 as essential for HDL assembly and as a regulator of VLDL secretion, linking it via PI3K to lipoprotein metabolism.","evidence":"Hepatocyte-specific ABCA1 KO mice, hepatoma ABCA1 siRNA, lipoprotein profiling, and PI3K activity assays","pmids":["22001232"],"confidence":"Medium","gaps":["Mechanism coupling ABCA1 to VLDL size control not resolved","PI3K-ABCA1 connection not biochemically defined"]},{"year":2012,"claim":"Showed that apoA-I/ABCA1 engagement activates JAK2/STAT3, PKA, PKC, and CDC42 signaling that feeds back on efflux, ABCA1 stability, and inflammation, casting ABCA1 as a signaling receptor.","evidence":"Pharmacological and genetic kinase modulation with efflux, stability, and inflammatory readouts (integrative study)","pmids":["22064972"],"confidence":"Medium","gaps":["Direct coupling of ABCA1 to each kinase not structurally mapped","Quantitative contribution of signaling versus transport to function unclear"]},{"year":2012,"claim":"Identified miR-33a as a direct post-transcriptional repressor of ABCA1 in islets, with rescue confirming the cholesterol-efflux/insulin-secretion causal link.","evidence":"Adenoviral miR-33a overexpression, anti-miRNA, cholesterol depletion, ABCA1 overexpression rescue, and insulin secretion assays","pmids":["22315319"],"confidence":"High","gaps":["Did not define additional miR-33a islet targets contributing to phenotype"]},{"year":2013,"claim":"Demonstrated astrocyte-specific control of brain apoE lipidation by ABCA1 and its role in restraining neuroinflammation and supporting microglial phagocytosis.","evidence":"Cell-type-specific (brain, neuron, astrocyte) ABCA1 conditional KO mice with LPS challenge and microglial phagocytosis assays","pmids":["23376685"],"confidence":"Medium","gaps":["Mechanism linking apoE loss to astrogliosis not resolved","Relationship to APOE genotype not addressed here"]},{"year":2014,"claim":"Identified HuR as a cholesterol-responsive RNA-binding protein that binds the ABCA1 3'UTR and enhances translation, adding translational control to ABCA1 regulation.","evidence":"RNA immunoprecipitation and HuR siRNA in Huh-7 and THP-1 cells with protein/mRNA and efflux assays","pmids":["24729624"],"confidence":"Medium","gaps":["Single lab; mechanism of cholesterol sensing by HuR not detailed","In vivo relevance not tested"]},{"year":2015,"claim":"Defined an LXR-independent route to ABCA1 induction through apoptotic-cell recognition (BAI1/ELMO1/Rac1), coupling efferocytosis to efflux capacity.","evidence":"BAI1-/-, ELMO1-/-, Rac1-deficient macrophages and BAI1 transgenic mice with ABCA1 induction and high-fat diet model","pmids":["26075824"],"confidence":"High","gaps":["Transcription factor downstream of Rac1 driving ABCA1 not identified","Quantitative contribution relative to LXR not established"]},{"year":2015,"claim":"Linked hyperglycemia to suppressed ABCA1 via loss of PRMT2-dependent LXR signaling, providing a diabetes-relevant regulatory mechanism.","evidence":"Normal/high glucose macrophages, PRMT2-/- mice, LXR reporter and efflux assays, diabetic mouse monocytes","pmids":["26288135"],"confidence":"Medium","gaps":["Direct PRMT2 substrate at the ABCA1 locus not identified","Single lab"]},{"year":2015,"claim":"Identified CXCL12/CXCR4 acting through GSK3β/β-catenin/TCF21 as a transcriptional repressor of ABCA1 in macrophages.","evidence":"Reporter and ChIP assays for TCF21, phospho-blots, CXCR4 inhibition, and lentiviral CXCL12 overexpression in ApoE-/- mice","pmids":["31662443"],"confidence":"Medium","gaps":["Direct TCF21 occupancy dynamics not fully resolved","Single lab"]},{"year":2015,"claim":"Showed TLR4/IRAK1 signaling downregulates ABCA1 and promotes lipid accumulation in vascular smooth muscle cells, extending ABCA1 inflammatory regulation beyond macrophages.","evidence":"IRAK1 siRNA in primary VSMCs and TLR4 KO mice on high-fat diet with oxLDL stimulation","pmids":["26512959"],"confidence":"Medium","gaps":["Transcription factor downstream of IRAK1 not defined","Single lab"]},{"year":2016,"claim":"Established AMPK as an activator of ABCA1 through induction of LXRα and its promoter binding, integrating energy sensing with efflux capacity.","evidence":"AMPK activation/knockdown, LXRα/β siRNA, ChIP, reporter, and efflux assays in human macrophages","pmids":["27343431"],"confidence":"Medium","gaps":["Direct AMPK substrate driving LXRα induction not identified","Single lab"]},{"year":2016,"claim":"Identified TRAK2 as a negative regulator of LXR-mediated ABCA1 expression, confirmed by ABCA1-dependent loss of the efflux phenotype.","evidence":"TRAK2 siRNA in THP-1 and HepG2, ChIP of LXR at promoter, efflux assays, ABCA1 KO cells","pmids":["28655204"],"confidence":"Medium","gaps":["Mechanism by which TRAK2 limits LXR promoter occupancy unclear","Single lab"]},{"year":2017,"claim":"Identified plasminogen as a non-HDL acceptor for ABCA1-mediated cholesterol efflux, inhibited by Lp(a).","evidence":"Apolipoprotein-deficient mouse models, plasma fractionation, proteomics, and human PLG efflux assays with ABCA1-expressing cells","pmids":["28768900"],"confidence":"Medium","gaps":["Physiological magnitude of PLG-dependent efflux unknown","Structural basis of PLG-ABCA1 interaction not defined"]},{"year":2017,"claim":"Defined AGE-albumin/RAGE signaling as an accelerant of ABCA1 degradation through ubiquitin-proteasome and lysosomal routes, distinct from baseline calpain-dependent turnover.","evidence":"Cycloheximide chase, proteasome/lysosome/calpain inhibitors, ubiquitination IP, and RAGE siRNA in THP-1","pmids":["29097054"],"confidence":"Medium","gaps":["E3 ligase mediating ABCA1 ubiquitination not identified","Single lab"]},{"year":2019,"claim":"Showed ABCA1 physically partners with PMP22 at the Schwann cell membrane to support apoE secretion and efflux, extending ABCA1 function to peripheral nerve lipid handling.","evidence":"Reciprocal co-IP from nerve lysates, PMP22 and ABCA1 KO mice, localization, efflux, and electrophysiology","pmids":["31061090"],"confidence":"Medium","gaps":["Functional consequence of PMP22-ABCA1 complex for myelination not resolved","Single lab"]},{"year":2019,"claim":"Linked APOE4 to impaired ABCA1 recycling via elevated ARF6, trapping ABCA1 in late endosomes and reducing efflux and Aβ degradation.","evidence":"ARF6 expression in APOE3/E4 astrocytes, ABCA1 localization, efflux assays, human CSF, and APOE4 targeted-replacement mice","pmids":["31641056"],"confidence":"Medium","gaps":["Mechanism by which ApoE4 elevates ARF6 not defined","Single lab"]},{"year":2019,"claim":"Defined an ABCA1-driven caveolin-1/eNOS/NO pathway regulating aqueous humor outflow and intraocular pressure, an efflux-independent vascular role.","evidence":"ABCA1 shRNA, LXR agonist GW3965, transendothelial resistance, NO/eNOS quantification, and intracameral injection in vivo","pmids":["32428234"],"confidence":"Medium","gaps":["Mechanism coupling ABCA1 to caveolin-1 suppression not defined","Single lab"]},{"year":2020,"claim":"Established ABCA1 as a myeloid tumor suppressor, with mutations enhancing IL-3Rβ/MAPK/JAK2 signaling and myeloproliferation that is reversed by apoA-I overexpression.","evidence":"CMML mutation sequencing, in vivo hematopoietic ABCA1 inactivation/mutant expression, signaling assays, and apoA-I transgene rescue","pmids":["32160545"],"confidence":"Medium","gaps":["How ABCA1 restrains IL-3Rβ signaling biochemically not resolved","Single study"]},{"year":2022,"claim":"Reframed the transport mechanism, showing ABCA1 extracts outer-leaflet phospholipids through a gateway/annulus hydrophobic tunnel rather than acting as an inner-to-outer floppase.","evidence":"Molecular dynamics simulations with gateway/annulus mutagenesis and lipid export assays","pmids":["35974019"],"confidence":"Medium","gaps":["Computational model awaits structural confirmation of the tunnel","Coupling to ATP hydrolysis cycle not directly demonstrated"]},{"year":2025,"claim":"Identified caveolin-1 as a sensor-driven mediator of ABCA1 endolysosomal trapping that activates mTORC1 and senescence in APOE4/AD models, reversible by cyclodextrin.","evidence":"Discovery proteomics, ABCA1 KO cells/mice, APOE4-TR mice, iPSC astrocytes, scRNA-seq, and cyclodextrin intervention","pmids":["39901180"],"confidence":"Medium","gaps":["Direct caveolin-1-ABCA1 interaction not biochemically resolved","Causal chain from trapping to mTORC1 not fully dissected"]},{"year":null,"claim":"How ATP hydrolysis is mechanically coupled to the gateway/annulus phospholipid extraction step, and how the many transcriptional, post-translational, and trafficking regulators are integrated into net efflux in vivo, remain unresolved.","evidence":"No single study reconciles the biochemical transport cycle with the layered regulatory network","pmids":[],"confidence":"Medium","gaps":["No experimental structure of the substrate-engaged transport cycle","Hierarchy among competing regulators in physiological tissue not established","Degradation E3 ligase(s) acting on ABCA1 not identified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[1]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[1]},{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[0,15]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[1,15]},{"term_id":"GO:0140104","term_label":"molecular carrier activity","supporting_discovery_ids":[0,2]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[2,6,15]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[3,14]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[20,25]}],"pathway":[{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[0]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,30]},{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[0,15]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[26,27,29]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[3,6]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[5,16,21]}],"complexes":[],"partners":["APOA1","STX13","FLOT1","OSBP","PMP22","TRAK2","ARF6","CAV1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O95477","full_name":"Phospholipid-transporting ATPase ABCA1","aliases":["ATP-binding cassette sub-family A member 1","ATP-binding cassette transporter 1","ABC-1","ATP-binding cassette 1","Cholesterol efflux regulatory protein"],"length_aa":2261,"mass_kda":254.3,"function":"Catalyzes the translocation of specific phospholipids from the cytoplasmic to the extracellular/lumenal leaflet of membrane coupled to the hydrolysis of ATP (PubMed:24097981, PubMed:35974019). Thereby, participates in phospholipid transfer to apolipoproteins to form nascent high density lipoproteins/HDLs (PubMed:14754908). Transports preferentially phosphatidylcholine over phosphatidylserine (PubMed:24097981). May play a similar role in the efflux of intracellular cholesterol to apolipoproteins and the formation of nascent high density lipoproteins/HDLs (PubMed:10533863, PubMed:14754908, PubMed:24097981, PubMed:35974019). Translocates phospholipids from the outer face of the plasma membrane and forces it through its gateway and annulus into an elongated hydrophobic tunnel in its extracellular domain (PubMed:35974019)","subcellular_location":"Cell membrane; Endosome","url":"https://www.uniprot.org/uniprotkb/O95477/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ABCA1","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ABCA1","total_profiled":1310},"omim":[{"mim_id":"619836","title":"HYPOALPHALIPOPROTEINEMIA, PRIMARY, 2, INTERMEDIATE","url":"https://www.omim.org/entry/619836"},{"mim_id":"618649","title":"HECT DOMAIN E3 UBIQUITIN PROTEIN LIGASE 1; HECTD1","url":"https://www.omim.org/entry/618649"},{"mim_id":"618463","title":"HYPOALPHALIPOPROTEINEMIA, PRIMARY, 2","url":"https://www.omim.org/entry/618463"},{"mim_id":"613574","title":"TETRATRICOPEPTIDE REPEAT DOMAIN-CONTAINING PROTEIN 39B; TTC39B","url":"https://www.omim.org/entry/613574"},{"mim_id":"613486","title":"MICRO RNA 33B; MIR33B","url":"https://www.omim.org/entry/613486"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Golgi apparatus","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/ABCA1"},"hgnc":{"alias_symbol":["TGD"],"prev_symbol":["ABC1","HDLDT1"]},"alphafold":{"accession":"O95477","domains":[{"cath_id":"-","chopping":"2-32_639-861","consensus_level":"medium","plddt":82.0266,"start":2,"end":861},{"cath_id":"-","chopping":"52-112_281-336_354-413_506-628_1540-1641","consensus_level":"medium","plddt":75.1429,"start":52,"end":1641},{"cath_id":"-","chopping":"122-277","consensus_level":"medium","plddt":65.6803,"start":122,"end":277},{"cath_id":"-","chopping":"414-504","consensus_level":"medium","plddt":67.9588,"start":414,"end":504},{"cath_id":"3.40.50.300","chopping":"895-1114","consensus_level":"high","plddt":82.1258,"start":895,"end":1114},{"cath_id":"3.30.70.250","chopping":"1125-1134_1180-1242","consensus_level":"medium","plddt":77.0812,"start":1125,"end":1242}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O95477","model_url":"https://alphafold.ebi.ac.uk/files/AF-O95477-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O95477-F1-predicted_aligned_error_v6.png","plddt_mean":73.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ABCA1","jax_strain_url":"https://www.jax.org/strain/search?query=ABCA1"},"sequence":{"accession":"O95477","fasta_url":"https://rest.uniprot.org/uniprotkb/O95477.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O95477/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O95477"}},"corpus_meta":[{"pmid":"19797709","id":"PMC_19797709","title":"Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses.","date":"2009","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19797709","citation_count":560,"is_preprint":false},{"pmid":"11483617","id":"PMC_11483617","title":"ABCA1. The gatekeeper for eliminating excess tissue cholesterol.","date":"2001","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/11483617","citation_count":353,"is_preprint":false},{"pmid":"17322896","id":"PMC_17322896","title":"Beta-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment.","date":"2007","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17322896","citation_count":348,"is_preprint":false},{"pmid":"16501936","id":"PMC_16501936","title":"Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL.","date":"2006","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/16501936","citation_count":297,"is_preprint":false},{"pmid":"10882340","id":"PMC_10882340","title":"ABCA1-mediated transport of cellular cholesterol and phospholipids to HDL apolipoproteins.","date":"2000","source":"Current opinion in lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/10882340","citation_count":236,"is_preprint":false},{"pmid":"26437365","id":"PMC_26437365","title":"MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels.","date":"2015","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/26437365","citation_count":213,"is_preprint":false},{"pmid":"12763760","id":"PMC_12763760","title":"Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene.","date":"2003","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12763760","citation_count":204,"is_preprint":false},{"pmid":"12615680","id":"PMC_12615680","title":"HDL apolipoproteins and ABCA1: partners in the removal of excess cellular cholesterol.","date":"2003","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12615680","citation_count":200,"is_preprint":false},{"pmid":"11111099","id":"PMC_11111099","title":"Tangier disease and ABCA1.","date":"2000","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/11111099","citation_count":185,"is_preprint":false},{"pmid":"15922656","id":"PMC_15922656","title":"Transcriptional regulatory networks in lipid metabolism control ABCA1 expression.","date":"2005","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/15922656","citation_count":172,"is_preprint":false},{"pmid":"29305383","id":"PMC_29305383","title":"Is ABCA1 a lipid transfer protein?","date":"2018","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/29305383","citation_count":142,"is_preprint":false},{"pmid":"33562440","id":"PMC_33562440","title":"The Role of the ATP-Binding Cassette A1 (ABCA1) in Human Disease.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33562440","citation_count":128,"is_preprint":false},{"pmid":"31641056","id":"PMC_31641056","title":"ApoE4 Alters ABCA1 Membrane Trafficking in Astrocytes.","date":"2019","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31641056","citation_count":125,"is_preprint":false},{"pmid":"22315319","id":"PMC_22315319","title":"miR-33a modulates ABCA1 expression, cholesterol accumulation, and insulin secretion in pancreatic islets.","date":"2012","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/22315319","citation_count":119,"is_preprint":false},{"pmid":"31524223","id":"PMC_31524223","title":"Quercetin protects against atherosclerosis by regulating the expression of PCSK9, CD36, PPARγ, LXRα and ABCA1.","date":"2019","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31524223","citation_count":118,"is_preprint":false},{"pmid":"25359426","id":"PMC_25359426","title":"ABCA1 and nascent HDL biogenesis.","date":"2014","source":"BioFactors (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25359426","citation_count":118,"is_preprint":false},{"pmid":"17478755","id":"PMC_17478755","title":"ABCA1-induced cell surface binding sites for ApoA-I.","date":"2007","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17478755","citation_count":116,"is_preprint":false},{"pmid":"11518753","id":"PMC_11518753","title":"Regulation and intracellular trafficking of the ABCA1 transporter.","date":"2001","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/11518753","citation_count":114,"is_preprint":false},{"pmid":"31831519","id":"PMC_31831519","title":"Brothers in Arms: ABCA1- and ABCG1-Mediated Cholesterol Efflux as Promising Targets in Cardiovascular Disease Treatment.","date":"2020","source":"Pharmacological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/31831519","citation_count":111,"is_preprint":false},{"pmid":"17991739","id":"PMC_17991739","title":"OSBP-related protein 8 (ORP8) suppresses ABCA1 expression and cholesterol efflux from macrophages.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17991739","citation_count":111,"is_preprint":false},{"pmid":"35192423","id":"PMC_35192423","title":"Molecular mechanisms for ABCA1-mediated cholesterol efflux.","date":"2022","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/35192423","citation_count":108,"is_preprint":false},{"pmid":"14560020","id":"PMC_14560020","title":"Retinoic acid receptor-mediated induction of ABCA1 in macrophages.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/14560020","citation_count":108,"is_preprint":false},{"pmid":"26075824","id":"PMC_26075824","title":"Apoptotic cells trigger a membrane-initiated pathway to increase ABCA1.","date":"2015","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/26075824","citation_count":102,"is_preprint":false},{"pmid":"19344785","id":"PMC_19344785","title":"The cell cholesterol exporter ABCA1 as a protector from cardiovascular disease and diabetes.","date":"2009","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/19344785","citation_count":96,"is_preprint":false},{"pmid":"27567858","id":"PMC_27567858","title":"ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies.","date":"2016","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/27567858","citation_count":96,"is_preprint":false},{"pmid":"22064972","id":"PMC_22064972","title":"The interaction of ApoA-I and ABCA1 triggers signal transduction pathways to mediate efflux of cellular lipids.","date":"2012","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/22064972","citation_count":94,"is_preprint":false},{"pmid":"12615681","id":"PMC_12615681","title":"Study of ABCA1 function in transgenic mice.","date":"2003","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12615681","citation_count":91,"is_preprint":false},{"pmid":"16500904","id":"PMC_16500904","title":"Purification and ATPase activity of human ABCA1.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16500904","citation_count":91,"is_preprint":false},{"pmid":"23990020","id":"PMC_23990020","title":"Pro-apoptotic miRNA-128-2 modulates ABCA1, ABCG1 and RXRα expression and cholesterol homeostasis.","date":"2013","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/23990020","citation_count":89,"is_preprint":false},{"pmid":"16118212","id":"PMC_16118212","title":"Unsaturated fatty acids phosphorylate and destabilize ABCA1 through a phospholipase D2 pathway.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16118212","citation_count":87,"is_preprint":false},{"pmid":"20570635","id":"PMC_20570635","title":"Placental ABCA1 and ABCG1 transporters efflux cholesterol and protect trophoblasts from oxysterol induced toxicity.","date":"2010","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/20570635","citation_count":84,"is_preprint":false},{"pmid":"16381920","id":"PMC_16381920","title":"Tetrahymena Genome Database (TGD): a new genomic resource for Tetrahymena thermophila research.","date":"2006","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/16381920","citation_count":82,"is_preprint":false},{"pmid":"23376685","id":"PMC_23376685","title":"ABCA1 influences neuroinflammation and neuronal death.","date":"2013","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/23376685","citation_count":81,"is_preprint":false},{"pmid":"21920460","id":"PMC_21920460","title":"Regulation of ABCA1 functions by signaling pathways.","date":"2011","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21920460","citation_count":79,"is_preprint":false},{"pmid":"16013195","id":"PMC_16013195","title":"ABCA1 and atherosclerosis.","date":"2005","source":"Vascular medicine (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16013195","citation_count":78,"is_preprint":false},{"pmid":"15358117","id":"PMC_15358117","title":"Serum amyloid A promotes ABCA1-dependent and ABCA1-independent lipid efflux from cells.","date":"2004","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15358117","citation_count":74,"is_preprint":false},{"pmid":"15528463","id":"PMC_15528463","title":"ABCA1 expression in carotid atherosclerotic plaques.","date":"2004","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/15528463","citation_count":71,"is_preprint":false},{"pmid":"30816508","id":"PMC_30816508","title":"MiR‑30e and miR‑92a are related to atherosclerosis by targeting ABCA1.","date":"2019","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/30816508","citation_count":70,"is_preprint":false},{"pmid":"33741356","id":"PMC_33741356","title":"The ABCA1-efferocytosis axis: A new strategy to protect against atherosclerosis.","date":"2021","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33741356","citation_count":65,"is_preprint":false},{"pmid":"12754274","id":"PMC_12754274","title":"Regulation of ABCA1 expression and cholesterol efflux during adipose differentiation of 3T3-L1 cells.","date":"2003","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/12754274","citation_count":64,"is_preprint":false},{"pmid":"19170766","id":"PMC_19170766","title":"Retroendocytosis pathway of ABCA1/apoA-I contributes to HDL formation.","date":"2008","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/19170766","citation_count":62,"is_preprint":false},{"pmid":"31336517","id":"PMC_31336517","title":"ABCA1 and metabolic syndrome; a review of the ABCA1 role in HDL-VLDL production, insulin-glucose homeostasis, inflammation and obesity.","date":"2019","source":"Diabetes & metabolic syndrome","url":"https://pubmed.ncbi.nlm.nih.gov/31336517","citation_count":61,"is_preprint":false},{"pmid":"22711909","id":"PMC_22711909","title":"Quercetin enhances ABCA1 expression and cholesterol efflux through a p38-dependent pathway in macrophages.","date":"2012","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/22711909","citation_count":61,"is_preprint":false},{"pmid":"15469992","id":"PMC_15469992","title":"Association of ABCA1 with syntaxin 13 and flotillin-1 and enhanced phagocytosis in tangier cells.","date":"2004","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/15469992","citation_count":61,"is_preprint":false},{"pmid":"21554545","id":"PMC_21554545","title":"Function and regulation of ABCA1--membrane meso-domain organization and reorganization.","date":"2011","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/21554545","citation_count":55,"is_preprint":false},{"pmid":"16505586","id":"PMC_16505586","title":"ABCA1 and biogenesis of HDL.","date":"2006","source":"Journal of atherosclerosis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/16505586","citation_count":53,"is_preprint":false},{"pmid":"32977800","id":"PMC_32977800","title":"Regulation of ATP binding cassette transporter A1 (ABCA1) expression: cholesterol-dependent and - independent signaling pathways with relevance to inflammatory lung disease.","date":"2020","source":"Respiratory research","url":"https://pubmed.ncbi.nlm.nih.gov/32977800","citation_count":53,"is_preprint":false},{"pmid":"31662443","id":"PMC_31662443","title":"CXCL12 promotes atherosclerosis by downregulating ABCA1 expression via the CXCR4/GSK3β/β-cateninT120/TCF21 pathway.","date":"2019","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/31662443","citation_count":52,"is_preprint":false},{"pmid":"16825673","id":"PMC_16825673","title":"Regulation of ABCA1 expression in human keratinocytes and murine epidermis.","date":"2006","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/16825673","citation_count":52,"is_preprint":false},{"pmid":"32894039","id":"PMC_32894039","title":"The crosstalk of ABCA1 and ANXA1: a potential mechanism for protection against atherosclerosis.","date":"2020","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/32894039","citation_count":51,"is_preprint":false},{"pmid":"35575923","id":"PMC_35575923","title":"ABCA1, ABCG1, and Cholesterol Homeostasis.","date":"2022","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/35575923","citation_count":50,"is_preprint":false},{"pmid":"16858612","id":"PMC_16858612","title":"ABCA1, from pathology to membrane function.","date":"2006","source":"Pflugers Archiv : European journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16858612","citation_count":49,"is_preprint":false},{"pmid":"23880356","id":"PMC_23880356","title":"Placental ABCA1 and ABCG1 expression in gestational disease: Pre-eclampsia affects ABCA1 levels in syncytiotrophoblasts.","date":"2013","source":"Placenta","url":"https://pubmed.ncbi.nlm.nih.gov/23880356","citation_count":49,"is_preprint":false},{"pmid":"18356690","id":"PMC_18356690","title":"Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes.","date":"2008","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18356690","citation_count":49,"is_preprint":false},{"pmid":"35743794","id":"PMC_35743794","title":"Role of ABCA1 in Cardiovascular Disease.","date":"2022","source":"Journal of personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35743794","citation_count":48,"is_preprint":false},{"pmid":"26109739","id":"PMC_26109739","title":"Increased Systemic and Plaque Inflammation in ABCA1 Mutation Carriers With Attenuation by Statins.","date":"2015","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26109739","citation_count":47,"is_preprint":false},{"pmid":"35530134","id":"PMC_35530134","title":"Remembering your A, B, C's: Alzheimer's disease and ABCA1.","date":"2022","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/35530134","citation_count":46,"is_preprint":false},{"pmid":"32575457","id":"PMC_32575457","title":"ABCA1/ApoE/HDL Signaling Pathway Facilitates Myelination and Oligodendrogenesis after Stroke.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32575457","citation_count":45,"is_preprint":false},{"pmid":"18450749","id":"PMC_18450749","title":"OSBP negatively regulates ABCA1 protein stability.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18450749","citation_count":45,"is_preprint":false},{"pmid":"31061090","id":"PMC_31061090","title":"PMP22 Regulates Cholesterol Trafficking and ABCA1-Mediated Cholesterol Efflux.","date":"2019","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31061090","citation_count":43,"is_preprint":false},{"pmid":"35974019","id":"PMC_35974019","title":"ABCA1 is an extracellular phospholipid translocase.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35974019","citation_count":42,"is_preprint":false},{"pmid":"28768900","id":"PMC_28768900","title":"Plasminogen promotes cholesterol efflux by the ABCA1 pathway.","date":"2017","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/28768900","citation_count":42,"is_preprint":false},{"pmid":"27343431","id":"PMC_27343431","title":"AMPK activates LXRα and ABCA1 expression in human macrophages.","date":"2016","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27343431","citation_count":41,"is_preprint":false},{"pmid":"24729624","id":"PMC_24729624","title":"RNA binding protein HuR regulates the expression of ABCA1.","date":"2014","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/24729624","citation_count":39,"is_preprint":false},{"pmid":"32155954","id":"PMC_32155954","title":"ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32155954","citation_count":39,"is_preprint":false},{"pmid":"19718435","id":"PMC_19718435","title":"LRP1 controls cPLA2 phosphorylation, ABCA1 expression and cellular cholesterol export.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19718435","citation_count":38,"is_preprint":false},{"pmid":"28028143","id":"PMC_28028143","title":"ABCA1/ApoE/HDL Pathway Mediates GW3965-Induced Neurorestoration After Stroke.","date":"2016","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/28028143","citation_count":37,"is_preprint":false},{"pmid":"22001232","id":"PMC_22001232","title":"Hepatic ABCA1 and VLDL triglyceride production.","date":"2011","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/22001232","citation_count":36,"is_preprint":false},{"pmid":"17884990","id":"PMC_17884990","title":"Expression and biological activity of ABCA1 in alveolar epithelial cells.","date":"2007","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17884990","citation_count":36,"is_preprint":false},{"pmid":"12706378","id":"PMC_12706378","title":"Expression, regulation, and activity of ABCA1 in human cell lines.","date":"2003","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12706378","citation_count":35,"is_preprint":false},{"pmid":"27862930","id":"PMC_27862930","title":"Piperine inhibits ABCA1 degradation and promotes cholesterol efflux from THP-1-derived macrophages.","date":"2016","source":"Molecular nutrition & food research","url":"https://pubmed.ncbi.nlm.nih.gov/27862930","citation_count":35,"is_preprint":false},{"pmid":"12452478","id":"PMC_12452478","title":"ABCA1: regulation, trafficking and association with heteromeric proteins.","date":"2002","source":"Annals of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12452478","citation_count":34,"is_preprint":false},{"pmid":"26288135","id":"PMC_26288135","title":"LXR-Mediated ABCA1 Expression and Function Are Modulated by High Glucose and PRMT2.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26288135","citation_count":34,"is_preprint":false},{"pmid":"22429094","id":"PMC_22429094","title":"Hesperetin upregulates ABCA1 expression and promotes cholesterol efflux from THP-1 macrophages.","date":"2012","source":"Journal of natural products","url":"https://pubmed.ncbi.nlm.nih.gov/22429094","citation_count":34,"is_preprint":false},{"pmid":"26512959","id":"PMC_26512959","title":"IRAK1 mediates TLR4-induced ABCA1 downregulation and lipid accumulation in VSMCs.","date":"2015","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/26512959","citation_count":34,"is_preprint":false},{"pmid":"17481640","id":"PMC_17481640","title":"ABCA1 expression in humans is associated with physical activity and alcohol consumption.","date":"2007","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/17481640","citation_count":33,"is_preprint":false},{"pmid":"20951680","id":"PMC_20951680","title":"PPARγ activates ABCA1 gene transcription but reduces the level of ABCA1 protein in HepG2 cells.","date":"2010","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/20951680","citation_count":33,"is_preprint":false},{"pmid":"37230281","id":"PMC_37230281","title":"QiShenYiQi pill inhibits atherosclerosis by promoting reverse cholesterol transport PPARγ-LXRα/β-ABCA1 pathway.","date":"2023","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37230281","citation_count":32,"is_preprint":false},{"pmid":"32062137","id":"PMC_32062137","title":"Molecular mechanism for nobiletin to enhance ABCA1/G1 expression in mouse macrophages.","date":"2020","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/32062137","citation_count":32,"is_preprint":false},{"pmid":"39901180","id":"PMC_39901180","title":"Cellular senescence induced by cholesterol accumulation is mediated by lysosomal ABCA1 in APOE4 and AD.","date":"2025","source":"Molecular neurodegeneration","url":"https://pubmed.ncbi.nlm.nih.gov/39901180","citation_count":31,"is_preprint":false},{"pmid":"33545111","id":"PMC_33545111","title":"Recent advances in the regulation of ABCA1 and ABCG1 by lncRNAs.","date":"2021","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33545111","citation_count":30,"is_preprint":false},{"pmid":"28655204","id":"PMC_28655204","title":"TRAK2, a novel regulator of ABCA1 expression, cholesterol efflux and HDL biogenesis.","date":"2017","source":"European heart journal","url":"https://pubmed.ncbi.nlm.nih.gov/28655204","citation_count":30,"is_preprint":false},{"pmid":"31805338","id":"PMC_31805338","title":"Impact of natural products on the cholesterol transporter ABCA1.","date":"2019","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31805338","citation_count":29,"is_preprint":false},{"pmid":"34943934","id":"PMC_34943934","title":"Geniposide Ameliorated Dexamethasone-Induced Cholesterol Accumulation in Osteoblasts by Mediating the GLP-1R/ABCA1 Axis.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34943934","citation_count":29,"is_preprint":false},{"pmid":"35829808","id":"PMC_35829808","title":"Cholesterol homeostasis regulated by ABCA1 is critical for retinal ganglion cell survival.","date":"2022","source":"Science China. Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35829808","citation_count":28,"is_preprint":false},{"pmid":"36055755","id":"PMC_36055755","title":"HDL, cholesterol efflux, and ABCA1: Free from good and evil dualism.","date":"2022","source":"Journal of pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36055755","citation_count":28,"is_preprint":false},{"pmid":"19828131","id":"PMC_19828131","title":"HIF-1beta determines ABCA1 expression under hypoxia in human macrophages.","date":"2009","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19828131","citation_count":28,"is_preprint":false},{"pmid":"36072007","id":"PMC_36072007","title":"Roles of ABCA1 in cancer.","date":"2022","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/36072007","citation_count":26,"is_preprint":false},{"pmid":"32428234","id":"PMC_32428234","title":"ABCA1 Regulates IOP by Modulating Cav1/eNOS/NO Signaling Pathway.","date":"2020","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/32428234","citation_count":25,"is_preprint":false},{"pmid":"29097054","id":"PMC_29097054","title":"AGE-albumin enhances ABCA1 degradation by ubiquitin-proteasome and lysosomal pathways in macrophages.","date":"2017","source":"Journal of diabetes and its complications","url":"https://pubmed.ncbi.nlm.nih.gov/29097054","citation_count":25,"is_preprint":false},{"pmid":"31101336","id":"PMC_31101336","title":"p62/mTOR/LXRα pathway inhibits cholesterol efflux mediated by ABCA1 and ABCG1 during autophagy blockage.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31101336","citation_count":24,"is_preprint":false},{"pmid":"36332025","id":"PMC_36332025","title":"Astrocytic dysfunction induced by ABCA1 deficiency causes optic neuropathy.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/36332025","citation_count":24,"is_preprint":false},{"pmid":"26729088","id":"PMC_26729088","title":"Silymarin Constituents Enhance ABCA1 Expression in THP-1 Macrophages.","date":"2015","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/26729088","citation_count":24,"is_preprint":false},{"pmid":"34940525","id":"PMC_34940525","title":"Genomic Variants and Multilevel Regulation of ABCA1, ABCG1, and SCARB1 Expression in Atherogenesis.","date":"2021","source":"Journal of cardiovascular development and disease","url":"https://pubmed.ncbi.nlm.nih.gov/34940525","citation_count":23,"is_preprint":false},{"pmid":"22115863","id":"PMC_22115863","title":"ABCA1, ABCG1, and SR-BI: Transit of HDL-associated sphingosine-1-phosphate.","date":"2011","source":"Clinica chimica acta; international journal of clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22115863","citation_count":23,"is_preprint":false},{"pmid":"31664073","id":"PMC_31664073","title":"LXRβ controls glioblastoma cell growth, lipid balance, and immune modulation independently of ABCA1.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/31664073","citation_count":23,"is_preprint":false},{"pmid":"26655293","id":"PMC_26655293","title":"ABCA1 agonist peptides for the treatment of disease.","date":"2016","source":"Current opinion in lipidology","url":"https://pubmed.ncbi.nlm.nih.gov/26655293","citation_count":23,"is_preprint":false},{"pmid":"32160545","id":"PMC_32160545","title":"ABCA1 Exerts Tumor-Suppressor Function in Myeloproliferative Neoplasms.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32160545","citation_count":22,"is_preprint":false},{"pmid":"16855366","id":"PMC_16855366","title":"Molecular defects in the ABCA1 pathway affect platelet function.","date":"2006","source":"Pathophysiology of haemostasis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/16855366","citation_count":22,"is_preprint":false},{"pmid":"18706283","id":"PMC_18706283","title":"Effect of ABCA1 mutations on risk for myocardial infarction.","date":"2008","source":"Current atherosclerosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/18706283","citation_count":22,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51069,"output_tokens":9099,"usd":0.144846,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19142,"output_tokens":8644,"usd":0.155905,"stage2_stop_reason":"end_turn"},"total_usd":0.300751,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"ABCA1 mediates active transport of cellular cholesterol and phospholipids to lipid-poor apolipoproteins (especially apoA-I), establishing the first step of reverse cholesterol transport and HDL particle formation. Loss-of-function mutations in ABCA1 cause Tangier disease.\",\n      \"method\": \"Genetic linkage/mutation analysis in Tangier disease patients combined with cellular cholesterol efflux assays\",\n      \"journal\": \"Current opinion in lipidology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — replicated across multiple labs, human genetic disease causation confirmed, cellular efflux assays consistent across studies\",\n      \"pmids\": [\"10882340\", \"11111099\", \"11483617\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Purified human ABCA1 reconstituted in liposomes displays robust ATPase activity that is stimulated preferentially by phosphatidylcholine and sphingomyelin, inhibited by cholesterol in a structure-specific manner (beta-sitosterol and campesterol inhibit; stigmasterol does not), and suppressed by glibenclamide, providing the first direct biochemical evidence of ABCA1 enzymatic mechanism.\",\n      \"method\": \"Purification of human ABCA1 from insect Sf9 cells, reconstitution in liposomes, in vitro ATPase assay with pharmacological and lipid modulators\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with purified protein, multiple substrate/inhibitor conditions tested in single rigorous study\",\n      \"pmids\": [\"16500904\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ABCA1 activity creates two types of high-affinity apoA-I binding sites at the cell surface: a low-capacity site formed by direct apoA-I/ABCA1 interaction (regulatory role, ~10% of surface-bound apoA-I) and a much higher-capacity site formed by apoA-I interacting with ABCA1-generated lipid domains (functions in nascent HDL assembly). The C-terminal domain of apoA-I is required for lipid-domain binding but not for direct ABCA1 binding.\",\n      \"method\": \"Radiolabeled apoA-I binding assays on J774 macrophages, covalent cross-linking to ABCA1, SDS-PAGE analysis, C-terminal deletion mutants of apoA-I\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — cross-linking, saturable binding analysis, mutagenesis of apoA-I, multiple orthogonal methods in single study\",\n      \"pmids\": [\"17478755\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ABCA1 and apoA-I undergo retroendocytosis via a clathrin- and Rab5-mediated pathway; approximately 30% of endocytosed ABCA1 is recycled back to the cell surface via a Rab4-mediated route. Blocking receptor-mediated endocytosis increases cell-surface ABCA1 but decreases apoA-I-mediated cholesterol efflux from cells with accumulated lipoprotein-derived cholesterol, indicating the retroendocytosis pathway contributes to HDL formation.\",\n      \"method\": \"Extracellular HA-tagged and intracellular GFP-tagged ABCA1 constructs, endocytosis/recycling assays, dominant-negative Rab GTPase constructs, cholesterol efflux assays\",\n      \"journal\": \"Genes to cells : devoted to molecular & cellular mechanisms\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal live-cell imaging and functional approaches, single lab\",\n      \"pmids\": [\"19170766\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Unsaturated fatty acids destabilize ABCA1 protein and impair lipid transport through a phospholipase D2 (PLD2)-dependent pathway: activated unsaturated acyl-CoA derivatives stimulate PLD2, which generates diacylglycerols that promote serine phosphorylation of ABCA1, leading to enhanced ABCA1 degradation.\",\n      \"method\": \"PLD inhibitor (1-butanol), PLD2 activator (mastoparan), PLD2 siRNA knockdown, acyl-CoA synthetase inhibitor (triacsin C), ABCA1 serine phosphorylation measurement, cholesterol efflux assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological and genetic (siRNA) approaches, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"16118212\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Retinoic acid receptors RARγ and RARα (but not RARβ) directly bind the DR4 element in the ABCA1 promoter and induce ABCA1 mRNA and protein expression in macrophages, operating through the same promoter element as LXR/RXR. In RARγ-/- macrophages, high RARα compensates for absent RARγ.\",\n      \"method\": \"Cellular cotransfection with RAR/RXR and ABCA1 promoter-reporter constructs, chromatin immunoprecipitation (ChIP), RARγ knockout mice, dose-response with ATRA and TTNPB\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirming in vivo promoter binding, cotransfection reporter assays, knockout validation, multiple methods single lab\",\n      \"pmids\": [\"14560020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ABCA1 directly associates with syntaxin 13 (but not syntaxins 3 or 6) and flotillin-1 in lipid raft microdomains and phagosomes. Syntaxin 13 siRNA knockdown reduces ABCA1 protein levels and decreases apoA-I-dependent choline-phospholipid efflux. ABCA1 is identified as a phagosomal protein involved in vesicular lipid transport.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence microscopy, siRNA knockdown of syntaxin 13, detergent-resistant microdomain fractionation, cholesterol/phospholipid efflux assay\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, immunofluorescence colocalization, siRNA functional validation, multiple methods single lab\",\n      \"pmids\": [\"15469992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Beta-cell-specific inactivation of Abca1 in mice causes markedly impaired glucose tolerance and defective insulin secretion (with normal insulin sensitivity), associated with altered islet cholesterol homeostasis. Rosiglitazone requires beta-cell Abca1 for its beneficial effects on glucose tolerance, establishing ABCA1 as a regulator of beta-cell cholesterol homeostasis and insulin secretion.\",\n      \"method\": \"Conditional beta-cell-specific ABCA1 knockout mice, glucose tolerance tests, insulin secretion assays in isolated islets in vitro, rosiglitazone treatment\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type-specific KO with defined metabolic phenotype, validated in vivo and in vitro, replicated by miR-33a study\",\n      \"pmids\": [\"17322896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"OSBP (oxysterol-binding protein) negatively regulates ABCA1 protein stability by a sterol-binding domain-dependent mechanism: OSBP silencing increases ABCA1 protein half-life by 3-fold without affecting ABCA1 mRNA or LXR transcriptional activity. A sterol-binding domain mutation in OSBP abolishes its destabilizing effect on ABCA1.\",\n      \"method\": \"RNAi knockdown of OSBP in CHO cells and J774 macrophages, ABCA1 half-life measurement (cycloheximide chase), ABCA1 mRNA quantification, OSBP domain mutant transfection, cholesterol efflux assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — protein stability assay, genetic (RNAi) and domain mutant approaches, multiple cell types, single lab\",\n      \"pmids\": [\"18450749\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ORP8 localizes to the endoplasmic reticulum, binds 25-hydroxycholesterol, and acts as a negative regulator of ABCA1 transcription in macrophages: ORP8 silencing by RNAi increases ABCA1 expression and cholesterol efflux to apoA-I, an effect partially mediated through the DR4 and E-box elements in the ABCA1 promoter and synergizing with LXR activation.\",\n      \"method\": \"ORP8 siRNA knockdown in THP-1 macrophages, ABCA1 promoter-luciferase reporter assay with DR4 and E-box mutations, subcellular localization by ER markers, cholesterol efflux assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA functional validation, reporter mutagenesis, single lab with multiple methods\",\n      \"pmids\": [\"17991739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"LRP1 deficiency increases PDGFRβ/MAPK signaling, leading to phosphorylation and activation of cytosolic phospholipase A2 (cPLA2), which releases arachidonic acid that suppresses LXR/RXR activation at the ABCA1 promoter, resulting in greatly reduced ABCA1 expression and impaired cholesterol efflux.\",\n      \"method\": \"LRP1-deficient cells, MAPK pathway inhibitors, cPLA2 phosphorylation assays, LXR/RXR reporter assays, ABCA1 expression and cholesterol efflux measurements\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and pharmacological dissection of pathway, single lab, multiple methods\",\n      \"pmids\": [\"19718435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"miR-33a directly suppresses ABCA1 expression in pancreatic islets via binding to the 3'UTR of ABCA1 mRNA, reducing glucose-stimulated insulin secretion and increasing islet cholesterol. miR-33a-induced insulin secretion defects are rescued by cholesterol depletion or ABCA1 overexpression, confirming the causal link between ABCA1-mediated cholesterol efflux and beta-cell function.\",\n      \"method\": \"Adenoviral miR-33a overexpression in human and mouse islets, anti-miRNA treatment, cholesterol depletion (methyl-β-cyclodextrin, mevastatin), ABCA1 overexpression in beta-cell-specific ABCA1 KO islets, glucose-stimulated insulin secretion assays\",\n      \"journal\": \"Diabetes\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple gain/loss-of-function approaches, rescue experiments, consistent with independent ABCA1 beta-cell KO study\",\n      \"pmids\": [\"22315319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"RNA-binding protein HuR directly binds the 3'UTR of ABCA1 mRNA (demonstrated by RNA immunoprecipitation) and increases ABCA1 translation. HuR silencing reduces ABCA1 protein expression and cholesterol efflux to apoA-I. Cellular cholesterol levels regulate HuR expression, localization, and its interaction with ABCA1 mRNA.\",\n      \"method\": \"RNA immunoprecipitation (RIP) assay, HuR siRNA knockdown in Huh-7 and THP-1 cells, ABCA1 protein and mRNA quantification, cholesterol efflux assays\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct RIP demonstrating mRNA binding, siRNA functional validation, single lab two cell types\",\n      \"pmids\": [\"24729624\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Apoptotic cells trigger ABCA1 upregulation via a plasma membrane-initiated signaling pathway involving the phagocytic receptor BAI1 (recognizing phosphatidylserine), and intracellular intermediates ELMO1 and Rac1. This pathway operates independently of LXR sterol-sensing machinery; macrophages from BAI1-/- mice show attenuated ABCA1 induction.\",\n      \"method\": \"BAI1-/-, ELMO1-/-, and Rac1-deficient primary macrophages, BAI1 transgenic mice overexpressing BAI1, ABCA1 mRNA and protein induction assays, high-fat diet in vivo model\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic KO models and transgenic rescue, in vivo validation, defined pathway components, single focused study\",\n      \"pmids\": [\"26075824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ApoE4 promotes greater ARF6 expression than ApoE3, trapping ABCA1 in late endosomes and impairing its recycling to the plasma membrane. This results in lower ABCA1-mediated cholesterol efflux, greater lipid-free ApoE4 particles, and lower Aβ degradation capacity. Enhancing ABCA1 activity reduces ApoE4 aggregation and ABCA1 aggregation in hippocampus.\",\n      \"method\": \"ARF6 expression measurement in APOE3 vs APOE4 astrocytes, ABCA1 subcellular localization by fluorescence microscopy, cholesterol efflux activity assays, human CSF from APOE3/3 vs APOE4/4 carriers, ApoE4 targeted replacement mice\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cellular localization with functional consequence, in vivo mouse model, human CSF validation, single lab\",\n      \"pmids\": [\"31641056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ABCA1 functions as an extracellular phospholipid translocase that extracts phospholipids from the outer leaflet of the plasma membrane (not as a floppase translocating from inner to outer leaflet). Simulations identified a gateway domain and annulus orifice forming a hydrophobic tunnel in the extracellular domain; engineered mutations in these domains strongly inhibit lipid export without affecting cell-surface ABCA1 expression.\",\n      \"method\": \"Molecular dynamics simulations, site-directed mutagenesis of gateway and annulus residues, ABCA1 cell-surface expression assays, lipid export functional assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — computational model supported by mutagenesis and functional assay, single study\",\n      \"pmids\": [\"35974019\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TRAK2 is a negative regulator of LXR-mediated ABCA1 expression: TRAK2 siRNA knockdown increases ABCA1 mRNA and protein, enhances cholesterol efflux to apoA-I and HDL, and increases LXR binding at the ABCA1 promoter (by ChIP). The effect of TRAK2 knockdown on cholesterol efflux is abolished in ABCA1-deficient cells, confirming ABCA1 dependence.\",\n      \"method\": \"TRAK2 siRNA in THP-1 and HepG2 cells, chromatin immunoprecipitation of LXR at ABCA1 promoter, ABCA1 mRNA/protein quantification, cholesterol efflux assays, ABCA1 KO cells\",\n      \"journal\": \"European heart journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, siRNA, ABCA1 KO rescue, multiple methods single lab\",\n      \"pmids\": [\"28655204\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Plasminogen (PLG) promotes cholesterol efflux specifically through the ABCA1 pathway, and this PLG-dependent efflux is inhibited by lipoprotein(a) [Lp(a)], identifying PLG as a non-HDL acceptor for ABCA1-mediated cholesterol efflux.\",\n      \"method\": \"Genetic mouse models (APOA1-, APOE-, APOA4-deficient), size-exclusion chromatography of plasma fractions, ion-exchange chromatography, shotgun proteomics, human PLG cholesterol efflux assays with ABCA1-expressing cells\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic models plus biochemical fractionation and proteomics, functional efflux assay, single study\",\n      \"pmids\": [\"28768900\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PMP22 physically interacts with ABCA1 at the Schwann cell plasma membrane (co-immunoprecipitation from nerve lysates); loss of PMP22 reduces ABCA1 membrane localization, decreases apoE secretion, and impairs ABCA1-mediated cholesterol efflux, while ABCA1 KO upregulates PMP22 expression.\",\n      \"method\": \"Co-immunoprecipitation from Schwann cell and nerve lysates, PMP22 KO and ABCA1 KO mice, immunofluorescence localization, cholesterol efflux assays, electrophysiology (membrane capacitance/resistance)\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP, KO mouse functional phenotype, multiple methods single lab\",\n      \"pmids\": [\"31061090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"High glucose inhibits LXR-dependent ABCA1 expression in macrophages through reduction of PRMT2 (protein arginine methyltransferase 2); PRMT2-/- macrophages have reduced ABCA1 expression and ABCA1-mediated cholesterol efflux, while monocytes from diabetic mice show decreased PRMT2.\",\n      \"method\": \"RAW 264.7 and BMDM cells in normal vs. high glucose, chromatin-modifying enzyme expression survey, PRMT2-/- mice, LXR reporter assays, ABCA1 expression and cholesterol efflux assays, diabetic mouse monocytes\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse validation, in vitro and in vivo correlation, single lab\",\n      \"pmids\": [\"26288135\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"AGE-albumin (advanced glycation end-products) accelerates ABCA1 degradation through both ubiquitin-proteasome and lysosomal pathways in macrophages, dependent on RAGE signaling (RAGE siRNA prevents ABCA1 reduction). Calpain inhibition does not rescue ABCA1 under AGE-albumin, unlike baseline ABCA1 degradation.\",\n      \"method\": \"Cycloheximide chase assay, proteasome inhibitor (MG-132), lysosomal inhibitor (ammonium chloride), calpain inhibitors, ABCA1 immunoprecipitation and ubiquitination assay, RAGE siRNA knockdown in THP-1 cells\",\n      \"journal\": \"Journal of diabetes and its complications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pathway inhibitors and RAGE siRNA, ubiquitination confirmed by IP, single lab\",\n      \"pmids\": [\"29097054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"AMPK activation increases ABCA1 and LXRα mRNA and protein in human macrophages through LXRα binding to the LXR responsive element in the ABCA1 promoter (confirmed by ChIP). LXRα silencing attenuates ABCA1 expression after AMPK activation; AMPK knockdown decreases ABCA1 and LXRα expression.\",\n      \"method\": \"Pharmacological and genetic AMPK activation/knockdown in THP-1 and primary human macrophages, LXRα/β siRNA, chromatin immunoprecipitation, luciferase reporter assay, cholesterol efflux assays\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, siRNA knockdown, reporter assays, single lab multiple methods\",\n      \"pmids\": [\"27343431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CXCL12, acting through CXCR4, activates the GSK3β/β-catenin(T120)/TCF21 signaling pathway to suppress ABCA1 transcription in macrophages: CXCL12 phosphorylates GSK3β and β-catenin(T120), inhibiting TCF21, which normally drives ABCA1 promoter activity. CXCR4 knockdown or inhibition blocks these effects.\",\n      \"method\": \"Luciferase reporter and ChIP assays for TCF21 binding at ABCA1 promoter, GSK3β/β-catenin phosphorylation by western blot, CXCR4 inhibition/knockdown, lentiviral CXCL12 overexpression in ApoE-/- mice, cholesterol efflux assays\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP, reporter assays, genetic in vivo validation, multiple methods single lab\",\n      \"pmids\": [\"31662443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ABCA1 modulates intraocular pressure by regulating aqueous humor outflow through a caveolin-1/endothelial NOS/NO signaling pathway: ABCA1 upregulation decreases caveolin-1 and increases eNOS expression and NO production in angular aqueous plexus cells, decreasing transendothelial resistance; ABCA1 downregulation has opposite effects. Intracameral injection of LXR agonist GW3965 decreases IOP in vivo.\",\n      \"method\": \"ABCA1 shRNA lentiviral knockdown, LXR agonist GW3965 treatment, transendothelial electrical resistance measurement, eNOS/caveolin-1/NO quantification, intracameral injection in animal model, IOP and outflow facility measurement\",\n      \"journal\": \"Investigative ophthalmology & visual science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain and loss of function with molecular pathway delineation, in vitro and in vivo, single lab\",\n      \"pmids\": [\"32428234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ABCA1 mutations in CMML patients confer a proliferative advantage to myeloid cells; mechanistically, ABCA1 mutations increase IL-3Rβ signaling via MAPK and JAK2, causing metabolic reprogramming. In vivo inactivation or expression of ABCA1 mutants in hematopoietic cells (in Tet2-/- background) promotes myeloproliferation. ApoA-I transgene overexpression dampens myeloproliferation, bypassing ABCA1 defects.\",\n      \"method\": \"Somatic mutation sequencing in CMML patients, in vivo hematopoietic ABCA1 inactivation and mutant expression in mice, IL-3Rβ/MAPK/JAK2 signaling assays, apoA-I transgene rescue\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KO and mutant expression with defined signaling pathway, human mutation data, single study\",\n      \"pmids\": [\"32160545\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Caveolin-1, a sensor of cellular cholesterol accumulation, promotes ABCA1 endolysosomal trafficking and lysosomal trapping. In APOE4 and AD models, oxysterol accumulation increases caveolin-1 and ABCA1 expression, trapping ABCA1 in lysosomes, activating mTORC1, and driving cellular senescence. Cyclodextrin treatment reduces brain oxysterol levels, ABCA1 lysosomal trapping, mTORC1 activation, and senescence markers in APOE4-TR mice.\",\n      \"method\": \"Unbiased discovery proteomics to identify caveolin-1 as ABCA1 trafficking mediator, ABCA1 KO cell lines and mouse models, APOE4-TR mice, iPSC-derived astrocytes, immunofluorescence/immunoblotting, scRNA-seq, cyclodextrin intervention\",\n      \"journal\": \"Molecular neurodegeneration\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — discovery proteomics plus KO validation plus in vivo rescue, single lab comprehensive study\",\n      \"pmids\": [\"39901180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Astrocyte-specific ABCA1 controls brain apoE levels in vivo; ABCA1-deficient astrocytes show reduced apoE, whereas neuronal ABCA1 deficiency does not affect apoE levels. Brain ABCA1 deficiency causes cortical astrogliosis, increased MAPK activation, and augmented TLR4-induced inflammatory responses. Microglia lacking ABCA1 show increased TNFα secretion and decreased phagocytosis.\",\n      \"method\": \"Brain-specific, neuron-specific, and astrocyte-specific ABCA1 conditional KO mice, LPS challenge, MAPK and inflammatory cytokine assays, microglial culture phagocytosis assays, apoE protein quantification\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific KO with defined inflammatory phenotype, multiple conditional KO lines, single lab\",\n      \"pmids\": [\"23376685\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"ABCA1 activity suppresses macrophage inflammation by modulating Toll-like receptor (TLR4) signaling; ABCA1 deficiency increases TLR4-mediated inflammatory cytokine and chemokine signaling, mechanistically linking cholesterol efflux to anti-inflammatory function through membrane lipid organization.\",\n      \"method\": \"ABCA1-deficient macrophages (from KO mice), TLR4 stimulation assays, inflammatory cytokine/chemokine measurement, sterol efflux assays\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO, defined inflammatory readout, replicated in human mutation carriers study\",\n      \"pmids\": [\"19797709\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ApoA-I/ABCA1 interaction activates multiple downstream signaling pathways including JAK2/STAT3, PKA, Rho family GTPase CDC42, and PKC. PKA and CDC42 activation regulate ABCA1-mediated lipid efflux; PKC activation stabilizes ABCA1 protein; JAK2/STAT3 activation regulates both lipid efflux and anti-inflammatory function.\",\n      \"method\": \"Pharmacological and genetic modulation of signaling kinases in ABCA1-expressing cells, lipid efflux assays, ABCA1 protein stability assays, anti-inflammatory readouts (reviewed and validated by multiple groups)\",\n      \"journal\": \"Molecular medicine (Cambridge, Mass.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple signaling pathways validated by pharmacological and genetic approaches across studies, review integrating original data\",\n      \"pmids\": [\"22064972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TLR4 signaling via IRAK1 downregulates ABCA1 expression and promotes lipid accumulation in vascular smooth muscle cells (VSMCs). IRAK1 siRNA knockdown reverses oxLDL/TLR4-induced ABCA1 downregulation. In TLR4 KO mice on a high-fat diet, IRAK1 expression and lipid accumulation are reduced with concomitant restoration of ABCA1.\",\n      \"method\": \"IRAK1 siRNA in primary cultured VSMCs, TLR4 KO mice on HFD, oxLDL stimulation, ABCA1 expression and lipid accumulation assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA functional validation and in vivo TLR4 KO, single lab\",\n      \"pmids\": [\"26512959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Hepatic ABCA1 is required for nascent HDL particle assembly; hepatocyte-specific ABCA1 KO (HSKO) mice show increased hepatic secretion of large TG-enriched VLDL1 particles, 50% lower LDL, and 80% reduction in HDL, with hypercatabolism of apoA-I by the kidney. Silencing ABCA1 in hepatoma cells reduces PI3K activation and increases secretion of large TG-enriched VLDL1, linking hepatic ABCA1 to VLDL metabolism.\",\n      \"method\": \"Hepatocyte-specific ABCA1 KO mice, ABCA1 siRNA in McArdle rat hepatoma cells, plasma lipoprotein profiling, VLDL secretion assays, PI3K activity measurement\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — tissue-specific KO with defined lipoprotein phenotype, cell-based siRNA validation, single lab\",\n      \"pmids\": [\"22001232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Piperine stabilizes ABCA1 protein by inhibiting calpain-mediated ABCA1 degradation, increasing ABCA1 half-life without affecting ABCA1 mRNA levels, thereby promoting cholesterol efflux from macrophages.\",\n      \"method\": \"Cycloheximide chase assay, calpain activity inhibition assay, ABCA1 mRNA and protein quantification in THP-1 macrophages, cholesterol efflux assays\",\n      \"journal\": \"Molecular nutrition & food research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pharmacological approach only, single lab, no direct calpain-ABCA1 reconstitution\",\n      \"pmids\": [\"27862930\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ABCA1 is an ATP-hydrolyzing integral membrane transporter that extracts phospholipids from the outer leaflet of the plasma membrane and flips them through a hydrophobic gateway/annulus tunnel into extracellular apoA-I, simultaneously generating lipid domains on the cell surface to which apoA-I binds (directly to ABCA1 at ~10% capacity and to lipid microdomains at ~90% capacity), enabling solubilization of cholesterol and phospholipids into nascent discoidal HDL particles; its activity is regulated transcriptionally by LXR/RXR, RAR, PPAR, AMPK-LXRα, HIF-1β, and multiple repressors (OSBP, ORP8, TRAK2, p62/mTOR), post-translationally by calpain-mediated degradation (destabilized by unsaturated fatty acid–activated PLD2 phosphorylation, AGE-RAGE-ubiquitin/lysosome pathways, and OSBP), and by endosomal recycling (clathrin/Rab5 endocytosis; Rab4/ARF6-regulated return to plasma membrane); beyond cholesterol efflux, ABCA1 suppresses TLR4-driven macrophage inflammation through membrane lipid raft remodeling, activates JAK2/STAT3, PKA, PKC, and CDC42 signaling upon apoA-I binding, controls beta-cell cholesterol homeostasis and insulin secretion, regulates hepatic VLDL secretion, modulates aqueous humor outflow via a caveolin-1/eNOS/NO pathway, maintains brain apoE lipidation and neuroinflammatory tone in an astrocyte-specific manner, and exerts tumor-suppressor function in myeloid cells by restraining IL-3Rβ/MAPK/JAK2 signaling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ABCA1 is an ATP-hydrolyzing integral membrane transporter that drives the rate-limiting first step of reverse cholesterol transport, exporting cellular cholesterol and phospholipids to lipid-poor apolipoproteins—principally apoA-I—to nucleate nascent HDL particles; loss-of-function mutations cause Tangier disease [#0]. The purified protein reconstituted in liposomes hydrolyzes ATP in a manner preferentially stimulated by phosphatidylcholine and sphingomyelin and inhibited by specific sterols, establishing its direct enzymatic mechanism [#1], and it operates as an extracellular phospholipid translocase that extracts outer-leaflet phospholipids through a hydrophobic gateway/annulus tunnel in its extracellular domain rather than as an inner-to-outer floppase [#15]. ABCA1 activity generates two classes of cell-surface apoA-I binding sites—a minor direct ABCA1/apoA-I site and a dominant high-capacity site formed by apoA-I engaging ABCA1-generated lipid domains, the latter requiring the apoA-I C-terminus and driving HDL assembly [#2]. ApoA-I binding additionally triggers JAK2/STAT3, PKA, PKC, and CDC42 signaling that feeds back on lipid efflux, protein stability, and inflammation [#28]. The transporter cycles between the plasma membrane and endosomes via clathrin/Rab5-mediated retroendocytosis with Rab4-dependent recycling that contributes to efflux [#3], and it partitions into lipid rafts and phagosomes in association with syntaxin 13 and flotillin-1 [#6]. ABCA1 abundance is tightly controlled transcriptionally—induced by LXR/RXR, RAR, and AMPK–LXRα, and repressed by ORP8, TRAK2, and CXCL12/CXCR4–GSK3β/TCF21 signaling [#5, #16, #21, #22]—and post-translationally through calpain-mediated degradation accelerated by PLD2-dependent serine phosphorylation, OSBP, and AGE–RAGE–ubiquitin/lysosomal pathways [#4, #8, #20]. Beyond efflux, ABCA1 restrains TLR4-driven macrophage inflammation through membrane lipid remodeling [#27], governs beta-cell cholesterol homeostasis and insulin secretion [#7, #11], directs hepatic HDL assembly and VLDL secretion [#30], maintains astrocyte apoE lipidation and neuroinflammatory tone [#26], and acts as a myeloid tumor suppressor by limiting IL-3Rβ/MAPK/JAK2 signaling [#24].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established ABCA1 as the molecular cause of defective cellular cholesterol efflux, defining the first step of reverse cholesterol transport and a human disease gene.\",\n      \"evidence\": \"Genetic linkage and mutation analysis in Tangier disease patients with cellular cholesterol efflux assays\",\n      \"pmids\": [\"10882340\", \"11111099\", \"11483617\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the enzymatic transport mechanism\", \"Did not define the lipid substrate or directionality of transport\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified retinoic acid receptors as direct transcriptional inducers of ABCA1 acting through the same promoter DR4 element as LXR/RXR, broadening the regulatory inputs controlling efflux capacity.\",\n      \"evidence\": \"Promoter-reporter cotransfection, ChIP, and RARγ knockout macrophages\",\n      \"pmids\": [\"14560020\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish physiological RAR ligand context\", \"Crosstalk with LXR occupancy not fully resolved\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Placed ABCA1 in lipid raft microdomains and phagosomes via direct association with syntaxin 13 and flotillin-1, linking it to vesicular lipid transport.\",\n      \"evidence\": \"Reciprocal co-IP, immunofluorescence, detergent-resistant microdomain fractionation, and syntaxin 13 siRNA\",\n      \"pmids\": [\"15469992\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which syntaxin 13 stabilizes ABCA1 not defined\", \"Phagosomal lipid handling role not quantified\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined a post-translational destabilization route in which unsaturated fatty acids drive PLD2-dependent serine phosphorylation and accelerated ABCA1 degradation, connecting lipid metabolism to transporter turnover.\",\n      \"evidence\": \"PLD inhibitors/activators, PLD2 siRNA, acyl-CoA synthetase inhibition, and phosphorylation/efflux assays\",\n      \"pmids\": [\"16118212\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase mediating ABCA1 serine phosphorylation not identified\", \"Link to calpain degradation pathway not directly tested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Provided the first direct biochemical proof of ABCA1 enzymatic activity, showing phospholipid-stimulated, sterol-modulated ATPase activity with purified reconstituted protein.\",\n      \"evidence\": \"Purification from Sf9 cells, liposome reconstitution, in vitro ATPase assays with lipid and pharmacological modulators\",\n      \"pmids\": [\"16500904\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve coupling of ATP hydrolysis to lipid movement\", \"Structural basis of sterol inhibition not defined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Resolved how apoA-I engages the cell surface, distinguishing a minor direct ABCA1-binding site from a dominant ABCA1-generated lipid-domain site responsible for HDL assembly.\",\n      \"evidence\": \"Radiolabeled apoA-I binding, cross-linking, and apoA-I C-terminal deletion mutants on macrophages\",\n      \"pmids\": [\"17478755\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular nature of the lipid domain not structurally defined\", \"Relative contribution of each site to net efflux not quantified\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrated a tissue-specific physiological role for ABCA1 in beta-cell cholesterol homeostasis and glucose-stimulated insulin secretion, extending function beyond vascular efflux.\",\n      \"evidence\": \"Beta-cell-specific Abca1 knockout mice with glucose tolerance and islet insulin secretion assays\",\n      \"pmids\": [\"17322896\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define how islet cholesterol controls secretion machinery\", \"ER ORP8-based transcriptional repression of ABCA1 awaits replication\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified ER-localized ORP8 as a sterol-sensing negative transcriptional regulator of ABCA1 acting through promoter DR4/E-box elements.\",\n      \"evidence\": \"ORP8 siRNA in THP-1 macrophages with promoter-luciferase mutagenesis and efflux assays\",\n      \"pmids\": [\"17991739\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; transcription factor linking ORP8 to promoter not identified\", \"In vivo relevance not established\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Established endosomal cycling as a functional determinant of ABCA1, showing clathrin/Rab5 retroendocytosis with Rab4-dependent recycling that supports efflux from lipid-loaded cells.\",\n      \"evidence\": \"Dual-tagged ABCA1 constructs, dominant-negative Rab GTPases, and efflux assays\",\n      \"pmids\": [\"19170766\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Sorting signals directing recycling versus degradation not mapped\", \"Fraction of efflux attributable to recycling not generalized across cell types\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified OSBP as a sterol-binding-domain-dependent destabilizer of ABCA1 protein, distinct from transcriptional control.\",\n      \"evidence\": \"OSBP RNAi, cycloheximide-chase half-life measurement, and OSBP domain mutants in CHO and J774 cells\",\n      \"pmids\": [\"18450749\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Degradation machinery engaged by OSBP not identified\", \"Direct OSBP-ABCA1 interaction not demonstrated\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Connected ABCA1-mediated efflux to anti-inflammatory function, showing ABCA1 deficiency amplifies TLR4 signaling through membrane lipid organization.\",\n      \"evidence\": \"ABCA1-deficient macrophages with TLR4 stimulation and cytokine/efflux readouts\",\n      \"pmids\": [\"19797709\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Precise lipid raft change driving TLR4 sensitization not defined\", \"Causal separation of efflux from membrane remodeling incomplete\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined an upstream signaling axis (LRP1 loss → PDGFRβ/MAPK → cPLA2 → arachidonic acid) that suppresses LXR-driven ABCA1 transcription.\",\n      \"evidence\": \"LRP1-deficient cells, MAPK inhibitors, cPLA2 phosphorylation, and LXR/RXR reporter and efflux assays\",\n      \"pmids\": [\"19718435\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; in vivo validation limited\", \"Mechanism of arachidonic acid LXR inhibition not detailed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established hepatic ABCA1 as essential for HDL assembly and as a regulator of VLDL secretion, linking it via PI3K to lipoprotein metabolism.\",\n      \"evidence\": \"Hepatocyte-specific ABCA1 KO mice, hepatoma ABCA1 siRNA, lipoprotein profiling, and PI3K activity assays\",\n      \"pmids\": [\"22001232\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism coupling ABCA1 to VLDL size control not resolved\", \"PI3K-ABCA1 connection not biochemically defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showed that apoA-I/ABCA1 engagement activates JAK2/STAT3, PKA, PKC, and CDC42 signaling that feeds back on efflux, ABCA1 stability, and inflammation, casting ABCA1 as a signaling receptor.\",\n      \"evidence\": \"Pharmacological and genetic kinase modulation with efflux, stability, and inflammatory readouts (integrative study)\",\n      \"pmids\": [\"22064972\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct coupling of ABCA1 to each kinase not structurally mapped\", \"Quantitative contribution of signaling versus transport to function unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identified miR-33a as a direct post-transcriptional repressor of ABCA1 in islets, with rescue confirming the cholesterol-efflux/insulin-secretion causal link.\",\n      \"evidence\": \"Adenoviral miR-33a overexpression, anti-miRNA, cholesterol depletion, ABCA1 overexpression rescue, and insulin secretion assays\",\n      \"pmids\": [\"22315319\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define additional miR-33a islet targets contributing to phenotype\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrated astrocyte-specific control of brain apoE lipidation by ABCA1 and its role in restraining neuroinflammation and supporting microglial phagocytosis.\",\n      \"evidence\": \"Cell-type-specific (brain, neuron, astrocyte) ABCA1 conditional KO mice with LPS challenge and microglial phagocytosis assays\",\n      \"pmids\": [\"23376685\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking apoE loss to astrogliosis not resolved\", \"Relationship to APOE genotype not addressed here\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified HuR as a cholesterol-responsive RNA-binding protein that binds the ABCA1 3'UTR and enhances translation, adding translational control to ABCA1 regulation.\",\n      \"evidence\": \"RNA immunoprecipitation and HuR siRNA in Huh-7 and THP-1 cells with protein/mRNA and efflux assays\",\n      \"pmids\": [\"24729624\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab; mechanism of cholesterol sensing by HuR not detailed\", \"In vivo relevance not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined an LXR-independent route to ABCA1 induction through apoptotic-cell recognition (BAI1/ELMO1/Rac1), coupling efferocytosis to efflux capacity.\",\n      \"evidence\": \"BAI1-/-, ELMO1-/-, Rac1-deficient macrophages and BAI1 transgenic mice with ABCA1 induction and high-fat diet model\",\n      \"pmids\": [\"26075824\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcription factor downstream of Rac1 driving ABCA1 not identified\", \"Quantitative contribution relative to LXR not established\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Linked hyperglycemia to suppressed ABCA1 via loss of PRMT2-dependent LXR signaling, providing a diabetes-relevant regulatory mechanism.\",\n      \"evidence\": \"Normal/high glucose macrophages, PRMT2-/- mice, LXR reporter and efflux assays, diabetic mouse monocytes\",\n      \"pmids\": [\"26288135\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct PRMT2 substrate at the ABCA1 locus not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified CXCL12/CXCR4 acting through GSK3β/β-catenin/TCF21 as a transcriptional repressor of ABCA1 in macrophages.\",\n      \"evidence\": \"Reporter and ChIP assays for TCF21, phospho-blots, CXCR4 inhibition, and lentiviral CXCL12 overexpression in ApoE-/- mice\",\n      \"pmids\": [\"31662443\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct TCF21 occupancy dynamics not fully resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed TLR4/IRAK1 signaling downregulates ABCA1 and promotes lipid accumulation in vascular smooth muscle cells, extending ABCA1 inflammatory regulation beyond macrophages.\",\n      \"evidence\": \"IRAK1 siRNA in primary VSMCs and TLR4 KO mice on high-fat diet with oxLDL stimulation\",\n      \"pmids\": [\"26512959\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcription factor downstream of IRAK1 not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established AMPK as an activator of ABCA1 through induction of LXRα and its promoter binding, integrating energy sensing with efflux capacity.\",\n      \"evidence\": \"AMPK activation/knockdown, LXRα/β siRNA, ChIP, reporter, and efflux assays in human macrophages\",\n      \"pmids\": [\"27343431\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct AMPK substrate driving LXRα induction not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified TRAK2 as a negative regulator of LXR-mediated ABCA1 expression, confirmed by ABCA1-dependent loss of the efflux phenotype.\",\n      \"evidence\": \"TRAK2 siRNA in THP-1 and HepG2, ChIP of LXR at promoter, efflux assays, ABCA1 KO cells\",\n      \"pmids\": [\"28655204\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which TRAK2 limits LXR promoter occupancy unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified plasminogen as a non-HDL acceptor for ABCA1-mediated cholesterol efflux, inhibited by Lp(a).\",\n      \"evidence\": \"Apolipoprotein-deficient mouse models, plasma fractionation, proteomics, and human PLG efflux assays with ABCA1-expressing cells\",\n      \"pmids\": [\"28768900\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological magnitude of PLG-dependent efflux unknown\", \"Structural basis of PLG-ABCA1 interaction not defined\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined AGE-albumin/RAGE signaling as an accelerant of ABCA1 degradation through ubiquitin-proteasome and lysosomal routes, distinct from baseline calpain-dependent turnover.\",\n      \"evidence\": \"Cycloheximide chase, proteasome/lysosome/calpain inhibitors, ubiquitination IP, and RAGE siRNA in THP-1\",\n      \"pmids\": [\"29097054\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase mediating ABCA1 ubiquitination not identified\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed ABCA1 physically partners with PMP22 at the Schwann cell membrane to support apoE secretion and efflux, extending ABCA1 function to peripheral nerve lipid handling.\",\n      \"evidence\": \"Reciprocal co-IP from nerve lysates, PMP22 and ABCA1 KO mice, localization, efflux, and electrophysiology\",\n      \"pmids\": [\"31061090\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of PMP22-ABCA1 complex for myelination not resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Linked APOE4 to impaired ABCA1 recycling via elevated ARF6, trapping ABCA1 in late endosomes and reducing efflux and Aβ degradation.\",\n      \"evidence\": \"ARF6 expression in APOE3/E4 astrocytes, ABCA1 localization, efflux assays, human CSF, and APOE4 targeted-replacement mice\",\n      \"pmids\": [\"31641056\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which ApoE4 elevates ARF6 not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined an ABCA1-driven caveolin-1/eNOS/NO pathway regulating aqueous humor outflow and intraocular pressure, an efflux-independent vascular role.\",\n      \"evidence\": \"ABCA1 shRNA, LXR agonist GW3965, transendothelial resistance, NO/eNOS quantification, and intracameral injection in vivo\",\n      \"pmids\": [\"32428234\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism coupling ABCA1 to caveolin-1 suppression not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established ABCA1 as a myeloid tumor suppressor, with mutations enhancing IL-3Rβ/MAPK/JAK2 signaling and myeloproliferation that is reversed by apoA-I overexpression.\",\n      \"evidence\": \"CMML mutation sequencing, in vivo hematopoietic ABCA1 inactivation/mutant expression, signaling assays, and apoA-I transgene rescue\",\n      \"pmids\": [\"32160545\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How ABCA1 restrains IL-3Rβ signaling biochemically not resolved\", \"Single study\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Reframed the transport mechanism, showing ABCA1 extracts outer-leaflet phospholipids through a gateway/annulus hydrophobic tunnel rather than acting as an inner-to-outer floppase.\",\n      \"evidence\": \"Molecular dynamics simulations with gateway/annulus mutagenesis and lipid export assays\",\n      \"pmids\": [\"35974019\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Computational model awaits structural confirmation of the tunnel\", \"Coupling to ATP hydrolysis cycle not directly demonstrated\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified caveolin-1 as a sensor-driven mediator of ABCA1 endolysosomal trapping that activates mTORC1 and senescence in APOE4/AD models, reversible by cyclodextrin.\",\n      \"evidence\": \"Discovery proteomics, ABCA1 KO cells/mice, APOE4-TR mice, iPSC astrocytes, scRNA-seq, and cyclodextrin intervention\",\n      \"pmids\": [\"39901180\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct caveolin-1-ABCA1 interaction not biochemically resolved\", \"Causal chain from trapping to mTORC1 not fully dissected\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ATP hydrolysis is mechanically coupled to the gateway/annulus phospholipid extraction step, and how the many transcriptional, post-translational, and trafficking regulators are integrated into net efflux in vivo, remain unresolved.\",\n      \"evidence\": \"No single study reconciles the biochemical transport cycle with the layered regulatory network\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No experimental structure of the substrate-engaged transport cycle\", \"Hierarchy among competing regulators in physiological tissue not established\", \"Degradation E3 ligase(s) acting on ABCA1 not identified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [0, 15]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [1, 15]},\n      {\"term_id\": \"GO:0140104\", \"supporting_discovery_ids\": [0, 2]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 6, 15]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [3, 14]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [20, 25]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 30]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [0, 15]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [26, 27, 29]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [3, 6]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [5, 16, 21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"APOA1\", \"STX13\", \"FLOT1\", \"OSBP\", \"PMP22\", \"TRAK2\", \"ARF6\", \"CAV1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}